

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number
WO 02/055518 A1

(51) International Patent Classification⁷: **C07D 403/10**,
487/04, 513/04, A61K 31/495, A61P 11/00, 27/02, 17/00
// (C07D 487/04, 209:00, 241:00) (C07D 487/04, C04D
241:00, C07D 241:00) (C07D 513/04, 241:00, 279:00)

(21) International Application Number: **PCT/JP01/11240**

(22) International Filing Date:
21 December 2001 (21.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PR 2373 2 January 2001 (02.01.2001) AU


(71) Applicant (for all designated States except US): **FUJISAWA PHARMACEUTICAL CO., LTD.** [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **TAKE, Kazukiko** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **KASAHARA, Chiyoshi** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **SHIGENAGA, Shinji** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **AZAMI, Hidenori** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **EIKYU, Yoshiteru** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **NAKAI, Kazuo** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **MORITA, Masataka** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

[Continued on next page]

(54) Title: 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPYPERAZINES AS TACHYKININ ANTAGONISTS



(57) Abstract: A compound of the formula (I): wherein in which R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹ are each as defined in the description, or a salt thereof. The object compound of the present invention has pharmacological activities such as Tachykinin antagonism, and is useful for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases.



WO 02/055518 A1

BEST AVAILABLE COPY





(74) Agent: **TABUSHI, Eiji**; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DESCRIPTION

1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS

5 TECHNICAL FIELD

The present invention relates to new benzhydryl derivatives and a salt thereof.

More particularly, it relates to new benzhydryl derivatives and a salt thereof which have pharmacological activities such as
10 Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like, to a process for preparation thereof, to a pharmaceutical composition comprising the same, and to a use of the same as a medicament.

Accordingly, one object of the present invention is to provide
15 new and useful benzhydryl derivatives and a salt thereof which have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like.

Another object of the present invention is to provide a
20 process for the preparation of said benzhydryl derivatives and a salt thereof.

A further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said benzhydryl derivatives and a pharmaceutically acceptable salt
25 thereof.

Still further object of the present invention is to provide a use of said benzhydryl derivatives or a pharmaceutically acceptable salt thereof as Tachykinin antagonist, especially Substance P antagonist, Neurokinin A antagonist or Neurokinin B antagonist,
30 useful for treating or preventing Tachykinin-mediated diseases, for example, respiratory diseases such as asthma, bronchitis, rhinitis, cough, expectoration, and the like; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria,
35 and other eczematoid dermatitis, and the like; inflammatory diseases


such as rheumatoid arthritis, osteoarthritis, and the like; pains or aches (e.g., migraine, headache, toothache, cancerous pain, back pain, etc.); and the like in human being or animals.

5


DISCLOSURE OF INVENTION

The object compound of the present invention can be represented by the following general formula (I):

10



15 wherein



in which

R^4 is hydrogen, lower alkanoyl or lower alkyl optionally substituted with carboxy, lower alkoxy carbonyl, pyridyl or lower alkylpyrazolyl,

35

- R^5 is hydrogen or lower alkoxy carbonyl,
 R^6 is hydrogen, halogen, oxo, hydroxy, lower alkanoyloxy,
cyano, carbamoyl or amino optionally substituted with
lower alkanoyl, hydroxy(lower)alkanoyl or
benzyloxycarbonyl,
 R^7 is hydrogen or halogen,
 R^8 is hydrogen, oxo, lower alkanoyloxy, azido or amino
optionally substituted with lower alkanoyl,
 R^9 is hydrogen; lower alkanoyl optionally substituted with
hydroxy, carboxy, lower alkoxy, phenyl(lower)alkoxy,
lower alkanoyloxy, lower alkoxy carbonyl, amino, lower
alkanoylamino, benzyloxy(lower)alkanoylamino,
hydroxy(lower)alkanoylamino, di(lower)alkylcarbamoyl or
mono(or di or tri)halogen(s); cyclo(lower)alkylcarbonyl
optionally substituted with hydroxy(lower)alkyl, amino
or lower alkanoylamino; azetidiny carbonyl; lower
alkylimidazolyl carbonyl; pyridyl carbonyl;
pyrimidinyl carbonyl; pyrazinyl carbonyl; lower alkyl
optionally substituted with imino, cyclo(lower)alkyl,
lower alkanoyl, lower alkoxy carbonyl, carbamoyl or
di(lower)alkylcarbamoyl; cyclo(lower)alkyl; carbamoyl
optionally substituted with mono(or di) (lower)alkyl(s);
aminosulfonyl optionally substituted with mono(or
di) (lower)alkyl(s); lower alkylsulfonyl optionally
substituted with hydroxy, lower alkylsulfonyl or lower
alkanoyloxy; or pyridyl,
 R^{10} is hydrogen or lower alkanoyl,
 R^{11} is hydrogen or oxo, and
 R^1 , R^2 and R^3 are independently hydrogen, halogen, lower alkyl,
lower alkoxy or tetrazolyl optionally substituted with mono(or
di or tri)halo(lower)alkyl.

It is to be noted that the object compound (I) may include one
or more stereoisomers due to asymmetric carbon atom(s) and double
bond, and all of such isomers and a mixture thereof are included



within the scope of the present invention.




It is further to be noted that isomerization or rearrangement of the object compound (I) may occur due to the effect of the light, acid, base or the like, and the compound obtained as the result of said isomerization or rearrangement is also included within the scope of the present invention.


It is also to be noted that the solvating form of the compound (I) (e.g. hydrate, etc.) and any form of the crystal of the compound (I) are included within the scope of the present invention.

According to the present invention, the object compound (I) or a salt thereof can be prepared by processes which are illustrated in the following schemes.


15 Process 1



Process 2Process 3

Process 4


wherein




R^{9a} is lower alkyl optionally substituted with hydroxy, carboxy,
 20 lower alkoxy, phenyl(lower)alkoxy, lower alkanoyloxy, lower
 alkoxy carbonyl, amino, lower alkanoylamino,
 benzyloxy(lower)alkanoylamino, hydroxy(lower)alkanoylamino,
 di(lower)alkylcarbamoyl or mono(or di or tri)halogen(s);
 cyclo(lower)alkyl optionally substituted with
 25 hydroxy(lower)alkyl, amino or lower alkanoylamino;
 azetidiny; lower alkylimidazolyl; pyridyl; pyrimidinyl; or
 pyrazinyl,

W_1 and W_2 are each a leaving group,

Y is



30 or its reactive derivative at the imino group [in which R^6 , R^7 , R^8 ,
 R^9 , R^{10} and R^{11} are each as defined above], and



[in which R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹ are each as defined above].

As to the starting compounds (II), (III), (IV), (V), (VI) and
 20 (VII), some of them are novel and can be prepared by the procedures
 described in the Preparations and Examples mentioned later or
 similar manners thereto.

Suitable salts of the starting and object compounds are
 conventional non-toxic and pharmaceutically acceptable salt and
 25 include an acid addition salt such as an organic acid salt (e.g.
 acetate, trifluoroacetate, fumarate, maleate, tartrate,
 methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.),
 an inorganic acid salt (e.g. hydrochloride, hydrobromide,
 hydroiodide, sulfate, nitrate, phosphate, etc.), or a salt with an
 30 amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.), or a
 metal salt such as an alkali metal salt (e.g. sodium salt, potassium
 salt, etc.) and an alkaline earth metal salt (e.g. calcium salt,
 magnesium salt, etc.), an ammonium salt, an organic base salt (e.g.
 trimethylamine salt, triethylamine salt, pyridine salt, picoline
 35 salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt,

etc.), or the like.

In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention intends to include within the scope thereof are explained in detail as follows.

The term "lower" is intended to mean 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise indicated.

10 Suitable "halogen" and "halogen" moiety in the term of "mono(or di or tri)halo(lower)alkyl" may include fluorine, chlorine, bromine and iodine.

15 Suitable "lower alkyl" and "lower alkyl" moiety in the terms of "mono(or di or tri)halo(lower)alkyl", "lower alkylamino", etc. may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl and the like, in which the preferred one is C₁-C₄ alkyl and the most preferred one is methyl, ethyl or isopropyl.

20 Suitable "cyclo(lower)alkyl" and "cyclo(lower)alkyl" moiety in the term of "cyclo(lower)alkylcarbonyl" may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, in which the preferred one is cyclo(C₃-C₆)alkyl and the most preferred one is cyclopropyl or cyclobutyl.


25 Suitable "lower alkoxy" and "lower alkoxy" moiety in the term of "lower alkoxy carbonyl" may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy and the like, in which the preferred one is C₁-C₄ alkoxy and the most preferred one is methoxy.

30 Suitable "lower alkanoyl" and "lower alkanoyl" moiety in the terms of "lower alkanoyloxy", etc. may include formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl and the like, in which the preferred one is C₁-C₄ alkanoyl and the most preferred one is acetyl, propoxy or
35 2-methylpropanoyl.

Suitable "leaving group" may include lower alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentoxy, etc.), aryloxy (e.g., phenoxy, naphthoxy, etc.), an acid residue or the like.

5 Suitable "acid residue" may be halogen (e.g., chlorine, bromine, iodine, etc.), sulfonyloxy (e.g., methanesulfonyloxy, phenylsulfonyloxy, mesitylenesulfonyloxy, toluenesulfonyloxy, etc.) or the like.

Preferred embodiments of the object compound (I) are as
10 follows:



In which

R^4 is lower alkanoyl or lower alkyl optionally substituted with carboxy, lower alkoxy, carbonyl, pyridyl or lower alkylpyrazolyl,

30 R^5 is hydrogen,

R^6 is halogen, oxo, hydroxy, lower alkanoyloxy, cyano, carbamoyl or amino optionally substituted with lower alkanoyl, hydroxy(lower)alkanoyl or benzyloxycarbonyl,

R^7 is hydrogen,

35 R^8 is hydrogen,


R^9 is lower alkanoyl substituted with hydroxy, carboxy, lower alkoxy, phenyl(lower)alkoxy, lower alkanoyloxy, lower alkoxy carbonyl, amino, lower alkanoylamino, benzyloxy(lower)alkanoylamino, hydroxy(lower)alkanoylamino, di(lower)alkylcarbamoyl or mono(or di or tri)halogen(s); cyclo(lower)alkylcarbonyl optionally substituted with hydroxy(lower)alkyl, amino or lower alkanoylamino; azetidiny carbonyl; lower alkylimidazolylcarbonyl; pyridylcarbonyl; pyrimidinylcarbonyl; pyrazinylcarbonyl; lower alkyl optionally substituted with imino, cyclo(lower)alkyl, lower alkanoyl, lower alkoxy carbonyl, carbamoyl or di(lower)alkylcarbamoyl; cyclo(lower)alkyl; carbamoyl optionally substituted with mono(or di) (lower)alkyl(s); aminosulfonyl optionally substituted with mono(or di) (lower)alkyl(s); lower alkylsulfonyl optionally substituted with hydroxy, lower alkylsulfonyl or lower alkanoyloxy; or pyridyl,

R^{10} is hydrogen or lower alkanoyl,

R^{11} is hydrogen or oxo, and

R^1 , R^2 and R^3 are independently hydrogen, halogen, lower alkyl, lower alkoxy or tetrazolyl optionally substituted with mono(or di or tri)halo(lower)alkyl.

More preferred embodiments of the object compound (I) are as follows:



in which

R⁴ is lower alkanoyl or lower alkyl optionally substituted with carboxy, lower alkoxycarbonyl, pyridyl or lower alkylpyrazolyl,

5 R⁵ is hydrogen,

R⁶ is halogen, oxo, hydroxy, lower alkanoyloxy, cyano, carbamoyl or amino optionally substituted with lower alkanoyl, hydroxy(lower)alkanoyl or benzyloxycarbonyl,

R⁷ is hydrogen,

10 R⁸ is hydrogen,

R⁹ is lower alkanoyl substituted with hydroxy, carboxy, lower alkoxy, phenyl(lower)alkoxy, lower alkanoyloxy, lower alkoxycarbonyl, amino, lower alkanoylamino, benzyloxy(lower)alkanoylamino,

15 hydroxy(lower)alkanoylamino, di(lower)alkylcarbamoyl or mono(or di or tri)halogen(s); cyclo(lower)alkylcarbonyl optionally substituted with hydroxy(lower)alkyl, amino or lower alkanoylamino; azetidiny carbonyl; lower alkylimidazolylcarbonyl; pyridylcarbonyl;

20 pyrimidinylcarbonyl; pyrazinylcarbonyl; lower alkyl optionally substituted with imino, cyclo(lower)alkyl, lower alkanoyl, lower alkoxycarbonyl, carbamoyl or di(lower)alkylcarbamoyl; cyclo(lower)alkyl; carbamoyl optionally substituted with mono(or di) (lower)alkyl(s); aminosulfonyl optionally substituted with mono(or

25 di) (lower)alkyl(s); lower alkylsulfonyl optionally substituted with hydroxy, lower alkylsulfonyl or lower alkanoyloxy; or pyridyl, and

R¹, R² and R³ are independently hydrogen, lower alkoxy or tetrazolyl

30 substituted with mono(or di or tri)halo(lower)alkyl.

The Processes 1, 2, 3 and 4 for preparing the object compound (I) of the present invention are explained in detail in the following.

Process 1

The object compound (I) or a salt thereof can be prepared by reacting the compound (II) or its reactive derivative at the imino group or a salt thereof with the compound (III) or a salt thereof.

5 Suitable reactive derivative at the imino group of the compound (II) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (II) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (II) with a silyl
10 compound such as bis(trimethylsilyl)acetamide, mono(trimethylsilyl)acetamide, bis(trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (II) with phosphorus trichloride or phosgene and the like.

 The reaction is usually carried out in a conventional solvent
15 such as water, alcohol (e.g. methanol, ethanol, etc.), acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof.

20 The reaction may also be carried out in the presence of a reductive reagent such as hydrides (e.g. hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, sodium triacetoxymethylborohydride, etc.), or the like.

 The reaction temperature is not critical, and the reaction is
25 usually carried out under cooling to heating.

Process 2

 The object compound (Ib) or a salt thereof can be prepared by reacting the compound (Ia) or a salt thereof with the compound (IV)
30 or a salt thereof.

 The reaction is usually carried out in a conventional solvent such as water, alcohol (e.g. methanol, ethanol, etc.), acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide,
35 pyridine or any other organic solvent which does not adversely

influence the reaction. These conventional solvents may also be used in a mixture with water.

The reaction may also be carried out in the presence of an inorganic or organic base such as alkali metal carbonate (e.g. potassium carbonate, etc.), alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkyl-morpholine, N,N-di(lower)alkylethylamine (e.g. N,N-diisopropylethylamine, etc.), N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

Process 3

The object compound (Ic) or a salt thereof can be prepared by cyclizing the compound (V) or its reactive derivative at the imino group or a salt thereof.

This reaction can be carried out in substantially the same manner as in Preparation 32.

Process 4

The object compound (Id) or a salt thereof can be prepared by reacting the compound (VI) or its reactive derivative at the imino group or a salt thereof with the compound (VII).

This reaction can be carried out in substantially the same manner as in Example 17.

25

The object compound (I) and a pharmaceutically acceptable salt thereof have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism or Neurokinin B antagonism, and therefore are useful for treating or preventing Tachykinin-mediated diseases, particularly Substance P-mediated diseases, for example, respiratory diseases such as asthma, bronchitis (e.g. chronic bronchitis, acute bronchitis and diffuse panbronchiolitis, etc.), rhinitis, cough, expectoration, and the like; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous

diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like; inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like; pains or aches (e.g. migraine, headache, cluster headache, toothache, cancerous pain, back pain, neuralgia, etc.); and the like.

Further, it is expected that the object compound (I) and a pharmaceutically acceptable salt thereof of the present invention are useful for treating or preventing ophthalmic diseases such as glaucoma, uveitis, and the like; gastrointestinal diseases such as ulcer, ulcerative colitis, irritable bowel syndrome, food allergy, and the like; inflammatory diseases such as nephritis, and the like; circulatory diseases such as hypertension, angina pectoris, cardiac failure, thrombosis, Raynaud's disease, and the like; epilepsy; spastic paralysis; pollakiuria; cystitis; bladder detrusor hyperreflexia; urinary incontinence; Parkinson diseases; dementia; AIDS related dementia; Alzheimer's diseases; Down's syndrome; Huntington's chorea; carcinoid syndrome; disorders related to immune enhancement or suppression; disorders caused by *Helicobacter pylori* or another spiral urease-positive gram-negative bacterium; sunburn; angiogenesis or diseases caused by angiogenesis; and the like.

It is furthermore expected that the object compound (I) and a pharmaceutically acceptable salt thereof of the present invention are useful for treating or preventing chronic obstructive pulmonary diseases, particularly chronic pulmonary emphysema; iritis; proliferative vitreoretinopathy; psoriasis; inflammatory intestinal diseases, particularly Crohn's diseases; hepatitis; superficial pain on congelation, burn, herpes zoster or diabetic neuropathy; telalgia attended to hyperlipidemia; postoperative neuroma, particularly of mastectomy; vulvar vestibulitis; hemodialysis-associated itching; lichen planus; laryngopharyngitis; bronchiectasis; coniosis; whooping cough; pulmonary tuberculosis; cystic fibrosis; emesis (e.g., nausea, retching, vomiting, acute emesis, delayed emesis, anticipatory emesis, post operative nausea and vomiting (PONV), acute and/or delayed emesis induced by drugs such as cancer chemotherapeutic agents, etc.); mental diseases, particularly

anxiety disorders, stress-related disorders, affective disorders, psychological development disorders and schizophrenia; demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis; attenuation of morphine withdrawal; oedema, such as
5 oedema caused by thermal injury; small cell carcinomas, particularly small cell lung cancer (SCLC); hypersensitivity disorders such as poison ivy; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; reflex sympathetic dystrophy such as shoulder/hand syndrome; addiction disorders such as alcoholism;
10 stress related somatic disorders; rheumatic diseases such as fibrositis; aggressive behaviour, optionally taking an antipsychotic agent together; mania or hypomania, optionally taking an antipsychotic agent together; symptoms associated with Premenstrual Syndrome (PMS) (PMS is also now referred to as Late Luteal Phase
15 Syndrome (LLS); psychosomatic disorders; psychoimmunologic disorders; attention deficit disorders (ADD) with or without hyperactivity; and the like.

Furthermore, the object compound (I) and a pharmaceutically acceptable salt thereof of the present invention are Central Nervous
20 System (CNS) penetrant.

For therapeutic purpose, the compound (I) and a pharmaceutically acceptable salt thereof of the present invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a
25 pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral, external including topical, internal, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal or transocular administration. The pharmaceutical preparations may be solid, semi-
30 solid or solutions such as capsules, tablets, pellets, dragees, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, cataplasms, gels, tapes, eye drops, solution, syrups, aerosols, suspension, emulsion, or the like. If desired, there may be included in these preparations, auxiliary substances,
35 stabilizing agents, wetting or emulsifying agents, buffers and other

commonly used additives.

While the dosage of the compound (I) will vary depending upon the age and condition of a patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the compound (I) may be effective for treating Tachykinin-mediated diseases such as asthma and the like. In general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.

In order to show the utility of the object compound (I) and a pharmaceutically acceptable salt thereof, the pharmacological test data of some representative compounds of the present invention is shown in the following.

Emesis in the dog

[I] Test Method

Individually housed adult female dogs (8 to 15 kg) were given an i.v. injection of a solution containing a test compound. 5 Min later the emetic responses (retching and vomiting) were induced by administration of subcutaneous apomorphine (0.1 mg/0.5 ml/kg) and observed for the next 60 min. The timing and number of retches and vomits observed were recorded for each animal. An individual animal was tested with at least 10 days between experiments.

[II] Test Result

The following Test Compounds showed 100% inhibition rate of emesis in the dog at the dose of 1.0 mg/kg.

Test compound: The object compounds of the Examples 52-(5), 52-(14) and 57-(1)

The following Preparations and Examples are given for the purpose of illustrating this invention.

Preparation 1

4N Hydrogen chloride in 1,4-dioxane (44 ml) was added to a solution of 4-tert-butoxycarbonyl-2-benzhydryl-1-methylpiperazine (6.5 g) in ethanol (33 ml) under ice-cooling over 30 minutes. The mixture was stirred at room temperature for 4 hours and evaporated under reduced pressure. The residue was triturated with diisopropyl ether and the resulting solid was collected by filtration to give 2-benzhydrylpiperazine dihydrochloride (6.02 g) as a powder.

NMR (DMSO- d_6 , δ): 2.50-3.95 (6H, m), 3.56 (3H, s), 4.30-5.50 (2H, m), 7.21-7.57 (11H, m)
MASS (APCI): 267 (M+H)⁺(free)

Preparation 2

3-Bromo-1,1-diphenyl-2-propanone (12.7 g) and N,N-diisopropylethylamine (15.7 ml) were added successively to a solution of (2S)-2-[(2-methoxybenzylamino)methyl]-pyrrolidine-1-carboxylic acid benzyl ester (15.6 g) in tetrahydrofuran (156 ml) at 0°C. After being stirred at room temperature for 2 hours, the mixture was poured into ice-water (100 ml) and extracted with ethyl acetate (100 ml x 2). The extract was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (3:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give a colorless syrup of (2S)-2-[N-(2-oxo-3,3-diphenylpropyl)-N-(2-methoxybenzyl)amino]methylpyrrolidine-1-carboxylic acid benzyl ester (1.51 g).

NMR (CDCl₃, δ): 1.30-2.00 (3H, m), 2.23-2.70 (2H, m), 3.11-3.93 (8H, m), 3.74 (3H, s), 5.06 (2H, m), 5.36 (1H, m), 6.82-7.31 (19H, m)
MASS (APCI): 563 (M+H)⁺

Preparation 3

A solution of dimethyl sulfoxide (0.219 ml) in dichloromethane

(1.1 ml) was added dropwise to a solution of oxalyl chloride (0.133 ml) in dichloromethane (2.7 ml) under cooling below -60°C with dry ice-acetone. After 5 minutes, the mixture was allowed to -10°C , and a solution of (2S)-1-benzyl-2-(hydroxymethyl)piperidine (156.5 mg) in dichloromethane (1.6 ml) was added to the mixture. The whole mixture was then cooled below -60°C and was stirred for 20 minutes at the same temperature. After addition of triethylamine (0.64 ml) followed by stirring at room temperature, the reaction mixture was poured into water and extracted with 1,2-dichloroethane. The extract was dried over magnesium sulfate and evaporated under reduced pressure to give a syrup. Benzylamine (0.33 ml) was added to the solution of the syrup obtained above procedure in 1,2-dichloroethane (2.5 ml) with ice-cooling. After the whole was stirred for 30 minutes at the same temperature, sodium triacetoxymethylborohydride (0.323 g) was added to this mixture. The reaction mixture was allowed to room temperature and was stirred for 3 hours. The mixture was poured into aqueous saturated sodium hydrogen carbonate solution and extracted with dichloromethane. The extract was dried over magnesium sulfate and evaporated under reduced pressure. The resulting residue was purified by silica gel chromatography using a mixture of dichloromethane and methanol (20:1) as an eluent to give N-benzyl-[(2S)-1-benzylpiperidin-2-ylmethyl]amine (168.5 mg).

NMR (CDCl_3 , δ): 1.26-1.49 (3H, m), 1.56-1.67 (3H, m), 2.03 (1H, s), 2.04-2.14 (1H, m), 2.42-2.50 (1H, m), 2.66-2.86 (3H, m), 3.25 (1H, d, $J=13.6\text{Hz}$), 3.73 (2H, s), 3.92 (1H, d, $J=13.6\text{Hz}$), 7.19-7.38 (20H, m)

MASS (APCI): 295 ($\text{M}+\text{H}$)⁺

30 Preparation 4

1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (2.11 g) was added over 5 minutes to a mixture of N,O-dimethylhydroxylamine hydrochloride (1.17 g), (2S)-piperazine-1,2,4-tricarboxylic acid 4-benzyl ester 1-tert-butyl ester (3.64 g), 1-hydroxybenzotriazole (1.49 g) and N,N-diisopropylethylamine (2.1 ml)

in dichloromethane (40 ml). After being stirred for 18 hours at room temperature, the resulting mixture was extracted with ethyl acetate. The extract was washed with brine, dried over sodium sulfate and evaporated under reduced pressure. The residue was
5 purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (3:1) to give 2-(N-methoxy-N-methylcarbamoyl)piperazine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester (3.61 g) as a colorless powder.

NMR (CDCl₃, δ): 1.45 (9H, s), 2.90-3.20 (5H, m), 3.60-4.20 (6H,
10 m), 4.41 (1H, m), 4.90 (1H, m), 5.06 (1H, d, J=12.4Hz), 5.16 (1H, d, J=12.4Hz), 7.33 (5H, m)

MASS (APCI): 308 (M-Boc+H)⁺

Preparation 5

15 Lithium aluminum hydride (38 mg) was added by small portions to an ice-cooled solution of 2-(N-methoxy-N-methylcarbamoyl)piperazine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester (407 mg) in tetrahydrofuran (5 ml) below 5°C under nitrogen atmosphere. After the mixture was stirred at the same
20 temperature for 2.5 hours, 2N sodium hydroxide (0.2 ml) was added to the mixture. After the mixture was stirred for 30 minutes, the insoluble materials were removed by filtration and washed with tetrahydrofuran. The filtrate and the washing were combined, and evaporated under reduced pressure to give a residue. Sodium
25 triacetoxyborohydride (424 mg) was added portionwisely to a stirred mixture of the residue obtained in the above procedure and 2-methoxybenzylamine (151 mg) in dichloromethane (4 ml). After being stirred at room temperature for 4 hours, 3-bromo-1,1-diphenyl-2-propanone (347 mg) in N,N-dimethylformamide (5 ml) and N,N-
30 diisopropylethylamine (0.35 ml) were added successively to the reaction mixture at 5°C. The whole mixture was stirred at room temperature for 36 hours and then poured into ice-water, and extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure.
35 The residue was purified by column chromatography on silica gel

using a mixed solvent of hexane and ethyl acetate (4:1) to give
(2R)-2-[N-(2-methoxybenzyl)-N-(2-oxo-3,3-diphenylpropyl)-
amino]methyl]piperazine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-
butyl ester (170 mg) as a colorless powder.

5 NMR (CDCl₃, δ): 1.41-1.57 (9H, m), 2.70-3.00 (5H, m), 3.25-4.35
 (11H, m), 4.95-5.15 (3H, m), 6.70-7.29 (19H, m)

Preparation 6

 Methanesulfonyl chloride (0.18 ml) was added dropwise to an
10 ice-cooled solution of tert-butyl (4R,7R,8aS)-4-benzhydryl-7-
 hydroxyhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (0.78 g)
 and triethylamine (0.53 ml) in dichlorometane. After being stirred
 for 3 hours at the same temperature the mixture was washed with
 aqueous saturated sodium hydrogen carbonate, dried over magnesium
15 sulfate and concentrated under reduced pressure. The syrup obtained
 by above procedure and sodium azide (126 mg) was dissolved into
 dimethylsulfoxide (5 ml). The whole was stirred at 75°C for 15
 hours. The mixture was poured into water and extracted with ethyl
 acetate. The extract was washed with brine, dried over magnesium
20 sulfate and concentrated under reduced pressure. The syrup was
 purified by column chromatography on silica gel using a mixed
 solvent of hexane and ethyl acetate (30:1). The fractions
 containing the objective compound were collected to give
 (4R,7S,8aS)-4-benzhydryl-2-(tert-

25 butoxycarbonyl)octahydropyrrolo[1,2-a]pyrazine-7-azide (0.70 mg).

 NMR (CDCl₃, δ): 1.30-1.40 (2H, m), 1.38 (9H, s), 1.98-2.06 (1H,
 m), 2.15-2.27 (2H, m), 2.31-2.65 (2H, m), 2.78 (1H, d,
 J=8.6Hz), 3.00-3.20 (1H, m), 3.63-3.72 (2H, m), 4.04 (1H,
 d, J=8.7Hz), 7.13-7.43 (10H, m)

30 MASS (APCI): 434 (M+H)⁺(free)

Preparation 7

 Acetic anhydride (25.3 μl) was added to an ice cooled
 solution of tert-butyl (4R,7S,8aS)-7-amino-4-
35 benzhydrylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (0.1 g)

and pyridine (0.096 ml) in dichloromethane (1 ml). After being stirred for 2 hours at the same temperature the mixture was poured into aqueous sodium hydrogen carbonate and extracted with dichloromethane. The organic layer was separated, dried over magnesium sulfate, concentrated under reduced pressure. The syrup was purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (4:1). The fractions containing the objective compound were collected to give tert-butyl (4R, 7S, 8aS)-7-(acetylamino)-4-benzhydrylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (110 mg) as a syrup.

MASS (APCI): 450 (M+H)⁺

Preparation 8

1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (Dess-Martin periodinane) (159 mg) was added into a solution of tert-butyl (4R, 7R, 8aS)-4-benzhydryl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (102.4 mg) in dichloromethane (1.5 ml) under ice-cooling. After being stirred for 1 hour at the same temperature, the reaction mixture was stirred for 2 hours at room temperature. Then the reaction mixture was poured into saturated aqueous sodium thiosulfate (5 ml), and the whole was stirred for 30 minutes. The aqueous mixture was extracted with dichloromethane. The extracts were washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a mixture of hexane and ethyl acetate (1:1) as an eluent. The fractions containing the objective compound were collected to give tert-butyl (4R, 8aS)-4-benzhydryl-7-oxohexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (76.5 mg).

NMR (CDCl₃, δ): 1.39 (9H, s), 1.96-2.09 (1H, m), 2.28-2.48 (2H, m), 2.60-2.71 (2H, m), 2.88 (1H, m), 3.12 (1H, d, J=17Hz), 3.41 (1H, m), 3.92-4.14 (3H, m), 7.16-7.39 (10H, m)

MASS (APCI): 407 (M+H)⁺

35 Preparation 9

(Diethylamino)sulfur trifluoride (124 mg) was added into a solution of tert-butyl (4R,8aS)-4-benzhydryl-7-oxohexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (69.5 mg) in 1,2-dichloroethane (1.5 ml) at room temperature. After being stirred for 2 days at the same temperature, the reaction mixture was poured into aqueous saturated sodium hydrogen carbonate. The aqueous layer was extracted with dichloromethane. The combined extracts were washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a mixture of hexane and ethyl acetate (2:1) as an eluent to give tert-butyl (4R,8aS)-4-benzhydryl-7,7-difluorohexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (37.2 mg).

NMR (CDCl₃, δ): 1.39 (9H, s), 2.04-4.18 (11H, m), 6.73-7.78 (10H, m)

MASS (APCI): 429 (M+H)⁺

Preparation 10

Triphenylphosphine (860 mg), acetic acid (159 mg) and diisopropyl azodicarboxylate were added successively into a solution of tert-butyl (4R,7R,8aS)-4-benzhydryl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (670 mg) in tetrahydrofuran (10 ml) at room temperature. After being stirred for 1 hour at room temperature, the reaction mixture was poured into aqueous saturated sodium hydrogen carbonate. The whole was extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure.

The resulting residue was purified by silica gel column chromatography with a mixture of hexane and ethyl acetate (2:1 - 3:2) as an eluent to give tert-butyl (4R,7S,8aS)-7-acetoxy-4-benzhydrylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate.

NMR (CDCl₃, δ): 1.30-1.43 (11H, m), 2.01-2.04 (3H, m), 2.08-2.79 (6H, m), 3.12 (1H, m), 3.77-4.10 (2H, m), 4.89-5.01 (1H, m), 6.71-7.42 (10H, m)

MASS (APCI): 451 (M+H)⁺

Preparation 11

The following compound was obtained according to a similar manner to that of Preparation 6.

5

tert-Butyl (4R, 7R, 8aS)-7-azido-4-benzhydrylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate

NMR (CDCl₃, δ): 1.38 (9H, s), 1.64-1.91 (3H, m), 2.40-2.60 (3H, m), 3.05-3.24 (2H, m), 3.82-4.18 (4H, m), 7.15-7.41 (10H, m)

10

MASS (APCI): 433 (M+H)⁺

Preparation 12

The following compound was obtained according to a similar manner to that of Preparation 7 from tert-butyl (4R, 7R, 8aS)-7-amino-4-benzhydrylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate.

tert-Butyl (4R, 7R, 8aS)-7-(acetylamino)-4-benzhydrylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate

20

NMR (CDCl₃, δ): 1.37 (9H, s), 1.71 (5H, m), 2.03 (1H, dd, J=3.3, 7.3Hz), 2.46-2.61 (2H, m), 2.94-3.07 (2H, m), 3.54-3.90 (4H, m), 4.21-4.28 (1H, m), 5.13-5.17 (1H, m), 7.15-7.42 (10H, m)

MASS (APCI): 450 (M+H)⁺

25

Preparation 13

To a solution of tert-butyl (4R, 7R, 8aS)-4-benzhydryl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (300 mg) in dichloromethane (2.5 ml) were added triethylamine (0.154 ml) and mesylchloride (68.2 μl) at 0°C. After stirring at 0°C for 1 hour, the mixture was quenched with water and extracted with ethyl acetate (x 3). The combined extracts were washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure to give 355.5 mg of solid. The mixture of the solid and sodium cyanide (150 mg) in dimethyl sulfoxide (2.5 ml) was stirred at 70°C for 5 hours.

35

Then, to the mixture was added sodium cyanide (396 mg). After stirring at 90°C overnight, the mixture was quenched with water (100 ml) and extracted with ethyl acetate (x 4). The combined extracts were washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified with preparative TLC (ethyl acetate/hexane = 1/1) to give tert-butyl (4R,7S,8aS)-4-benzhydryl-7-cyano-hexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (205 mg) as an oil.

IR (KBr): 2241, 1693 cm^{-1}

10 NMR (CDCl_3 , δ): 1.38 (9H, s), 1.60-1.72 (1H, m), 2.04-2.82 (6H, m), 2.98-3.03 (1H, m), 3.10-3.30 (1H, m), 3.65-3.85 (1H, m), 4.04 (1H, d, $J=8.3\text{Hz}$), 4.02-4.25 (1H, m), 7.13-7.43 (10H, m)

MASS (APCI+): 418 (M+H)

15

Preparation 14

To a solution of tert-butyl (4R,7S,8aS)-4-benzhydryl-7-cyano-hexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (94 mg) and tetrabutylammonium hydrogensulfate (122 mg) in dichloromethane (1 ml) were added 30% hydrogen peroxide (0.41 ml) and 30% sodium hydroxide aqueous solution (0.41 ml). After stirring at room temperature overnight, the mixture was extracted with dichloromethane (x 4). The combined extracts were washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified with preparative TLC (ethyl acetate) to give two fractions. The upper fraction gave the starting material as an oil (24.1 mg). The lower fraction gave tert-butyl (4R,7S,8aS)-4-benzhydryl-7-carbamoylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (39.4 mg) as a white solid.

30 NMR (CDCl_3 , δ): 1.20-1.70 (1H, m), 1.39 (9H, s), 2.04-2.29 (3H, m), 2.40-2.70 (3H, m), 3.08 (1H, d, $J=9.7\text{Hz}$), 3.00-3.20 (1H, m), 3.85-3.95 (1H, m), 4.00-4.30 (1H, m), 4.16 (1H, d, $J=7.5\text{Hz}$), 4.88 (1H, brs), 6.24 (1H, brs), 7.19-7.35 (10H, m)

35 MASS (APCI+): 435 (M+H)

Preparation 15

The following compound was obtained according to a similar manner to that of Example 15.

5

(4R, 8aS)-7-Amino-4-benzhydrylhexahydropyrrolo[1,2-a]pyrazine-2-carboxylic acid tert-butyl ester

MASS (ES⁺): 466.4 (M+1), 488.4 (M+Na)⁺

10 Preparation 16

To a solution of ethyl 1-hydroxymethyl-1-cyclopropanecarboxylate (134 mg) in dichloromethane (1.5 ml) were added imidazole (82.3 mg), and tert-butyldimethylsilyl chloride (154 mg) at room temperature. After being stirred at the same temperature for 20 hours, the solution was partitioned between ethyl acetate and water, while the aqueous layer was adjusted at pH 3 with diluted hydrochloric acid. The organic layer was washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (6 g) using a mixed solvent of hexane and ethyl acetate (5:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give ethyl 1-[(tert-butyldimethylsilyloxy)methyl]-1-cyclopropanecarboxylate (260 mg) as colorless oil.

25 IR (Neat): 2952, 2860, 1726, 1466, 1255, 1171, 1097 cm⁻¹

NMR (CDCl₃, δ): -0.07-0.11 (6H, m), 0.81-0.90 (11H, m), 1.02-1.11 (2H, m), 1.20 (3H, t, J=7.1Hz), 3.79 (2H, s), 4.08 (2H, q, J=7.1Hz)

MASS (API-ES): 281 (M+Na)⁺

30

Preparation 17

To a solution of ethyl 1-[(tert-butyldimethylsilyloxy)methyl]-1-cyclopropane carboxylate (250 mg) in ethanol (1.5 ml) was added 1N sodium hydroxide (0.97ml) under ice-cooling. After being stirred at room temperature for 20 hours, the reaction mixture was adjusted at

35

pH 4 with diluted hydrochloric acid, and the whole was concentrated under reduced pressure. The residue was partitioned between ethyl acetate and diluted hydrochloric acid. The organic layer was separated, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (6 g) using a mixed solvent of dichloromethane and methanol (20:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give 1-[(tert-butyldimethylsiloxy)methyl]-1-cyclopropanecarboxylic acid (85 mg) as colorless oil.

IR (Neat): 2952, 2860, 1693, 1248, 1099 cm^{-1}

NMR (CDCl_3 , δ): -0.02-0.12 (6H, m), 0.85-1.40 (13H, m), 3.80 (2H, s)

MASS (API-ES): 253 (M+Na)⁺

15

Preparation 18

To a solution of (4R, 9aR)-8-acetyl-4-benzhydryl-2-(2-methoxybenzyl)octahydro-2H-pyrazino[1,2-a]pyrazine (5.9 g) in dichloroethane (60 ml) was added 1-chloroethyl chloroformate (2.3 ml) at room temperature, and the reaction mixture was heated at 70°C for 30 minutes with stirring. After removal of solvent by evaporation, to the resulting residue was added methanol (45 ml), and the solution was refluxed for 40 minutes. After being concentrated, the residue was triturated with diisopropyl ether. The resulting precipitate was collected by filtration and dried under reduced pressure for 5 hours at 40°C to give (4R, 9aR)-8-acetyl-4-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (3.1 g) as colorless foam.

NMR ($\text{DMSO}-d_6$, δ): 1.90-2.00 (3H, m), 2.20-4.70 (13H, m), 7.10-7.50 (10H, m), 9.65 (2H, br)

30

MASS (APCI): 350 (M+H)⁺(free)

Preparation 19

Under nitrogen atmosphere, to a solution of (2S)-2-ethoxycarbonylpiperazine-1,4-dicarboxylic acid 4-benzyl ester 1-

35

tert-butyl ester (9.35 g) was added portionwise lithium borohydride (1.82 g), and the reaction mixture was stirred for 90 minutes. After methanol (2.32 ml) was added dropwise to the solution under ice-cooling, the mixture was stirred at room temperature for 17 hours. 1N Hydrochloric acid (80 ml) was added dropwise under ice-cooling, and ethyl acetate (100 ml) and sodium chloride (6 g) was added to it. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure to give colorless oil. The oil was purified by column chromatography on silica gel (90 g) using a mixed solvent of hexane and ethyl acetate (3:2). The fractions containing the objective compound were collected and evaporated under reduced pressure to give (2S)-2-(hydroxymethyl)piperazine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester (8.40 g) as a colorless oil.

NMR (CDCl₃, δ): 1.46 (9H, s), 2.40-4.30 (10H, m), 5.10-5.30 (2H, m), 7.30-7.50 (5H, m)

MASS (API-ES): 373 (M+Na)⁺

Preparation 20

Under nitrogen atmosphere, to a solution of oxalyl chloride (1.64 ml) in dichloromethane (34 ml) under -65°C, was added dropwise a solution of dimethyl sulfoxide (2.0 ml) in dichloromethane (15 ml) and stirred for 10 minutes at the same temperature. A solution of (2S)-2-(hydroxymethyl)piperazine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester (3.29 g) in dichloromethane (24 ml) was dropped into the above solution over 5 minutes under -65°C. The reaction mixture was stirred at the same temperature for 15 minutes, then stirred at -45°C for 90 minutes. Triethylamine (7.85 ml) was added to the solution under -40°C, and the mixture was stirred at 0°C for 20 minutes. The mixture was poured into saturated aqueous ammonium chloride (100 ml). The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give (2R)-2-formylpiperazine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester (3.33 g) as a colorless syrup.

NMR (CDCl₃, δ): 1.40-1.70 (9H, m), 2.85-3.30 (3H, m), 3.70-

4.80 (4H, m), 5.05-5.30 (2H, m), 7.30-7.40 (5H, m), 9.58
(1H, s)

MASS (API-ES): 371 (M+Na)⁺

5 Preparation 21

Under nitrogen atmosphere, to a solution of (2R)-2-formylpiperazine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester (2.64 g) and 3-(2-methoxybenzylamino)-1,1-diphenylpropan-2-one (3.66 g) in dichloromethane (30 ml) was added acetic acid (0.607 ml)
10 and sodium tritacetoxyborohydride (4.82 g) under ice-cooling, and then it was stirred at room temperature for 3 hours. The reaction mixture was poured into aqueous sodium hydrogen carbonate (100 ml) and extracted with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate, and evaporated under reduced
15 pressure. The resulting residue was purified by column chromatography on silica gel (82 g) using a mixed solvent of hexane and ethyl acetate (3:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give (2S)-2-[[N-(2-methoxybenzyl)-N-(2-oxo-3,3-
20 diphenylpropyl)amino]methyl]piperazine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester (3.24 g) as a syrup.

NMR (CDCl₃, δ): 1.40-1.65 (9H, m), 2.65-5.40 (19H, m), 6.70-
7.40 (19H, m)

MASS (APCI): 678 (M+H)⁺

25

Preparation 22

The following compound was obtained according to a similar manner to that of Preparation 4.

30 (R)-3-(N-Methoxy-N-methylcarbamoyl)thiomorpholine-4-carboxylic acid tert-butyl ester

IR (neat): 1695, 1676, 1454, 1394, 1371, 1317, 1163 cm⁻¹

NMR (CDCl₃, δ): 1.46 (9H, s), 2.50-2.86 (2H, m), 2.93 (1H, dd,
J=14.2, 4.9Hz), 3.05 (1H, dd, J=4.2, 14.2Hz), 3.22 (3H,
35 s), 3.77 (3H, s), 3.77 (1H, brs), 4.18 (1H, brs), 5.25

(1H, brs)

MASS (APCI): 190.8 (M-Boc)⁺

Preparation 23

5 The following compound was obtained according to a similar manner to the first step of Preparation 5.

(R)-3-Formylthiomorpholine-4-carboxylic acid tert-butyl ester

IR (neat): 1693 cm⁻¹

10 MASS (ES⁻): 230.2 (M-H)⁺

Preparation 24

The following compound was obtained according to a similar manner to that of Preparation 3.

15

(R)-3-[(2-Methoxybenzyl)amino]methyl]thiomorpholine-4-carboxylic acid tert-butyl ester

IR (neat): 1691, 1460, 1412, 1367, 1248, 1163 cm⁻¹

20 NMR (CDCl₃, δ): 1.46 (9H, s), 2.35 (1H, brd, J=13.0Hz), 2.54-2.68 (1H, m), 2.71 (1H, dd, J=3.0, 13.0Hz), 2.85-3.15

(4H, m), 3.81 (2H, s), 3.83 (3H, s), 4.24 (1H, brs),

4.48 (1H, brs), 6.80-7.32 (4H, m)

MASS (ES⁺): 353.2 (M+H)⁺, 375.3 (M+Na)⁺

25 Preparation 25

The following compound was obtained according to a similar manner for to that of Preparation 2.

30 (R)-3-[[N-(2-Methoxybenzyl)-N-(2-oxo-3,3-diphenylpropyl)amino]methyl]thiomorpholine-4-carboxylic acid tert-butyl ester

IR (neat): 1723, 1685, 1240, 1159 cm⁻¹

NMR (CDCl₃, δ): 1.41 (9H, s), 2.27 (1H, brd, J=12.9Hz), 2.55

35 (1H, dd, J=2.9, 12.3Hz), 2.50-2.96 (5H, m), 3.19 (1H, brs), 3.40 (1H, d, J=17.2Hz), 3.53 (1H, d, J=17.2Hz),

3.66 (1H, J=13.7Hz), 3.74 (3H, s), 3.90 (1H, d, J=13.7Hz), 4.12 (1H, brs), 4.36 (1H, brs), 6.74-7.38 (14H, m)

MASS (APCI): 561 (M+H)⁺

5

Preparation 26

The following compound was obtained according to a similar manner to that of Preparation 18.

10 (6R, 9aR)-6-Benzhydryloctahydropyrazino[2,1-c][1,4]thiazine dihydrochloride

MASS (APCI): 324 (M+H)⁺(free)

Preparation 27

15 Sodium triacetoxyborohydride (127 mg) was added portionwise to a mixture of 2-benzhydrylpiperazine dihydrochloride (97.6 mg), N,N-diisopropylethylamine (0.104 ml) and 2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]benzaldehyde (61.2 mg) in a mixture of dichloromethane (5 ml) and acetic acid (1 drop) at 0°C and the whole was stirred at 5°C - room temperature overnight. The mixture was partitioned between ethyl acetate and 2N sodium hydroxide. The organic layer was separated, washed with brine, dried over sodium sulfate and evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel using a mixed solvent of dichloromethane and methanol (70:1). The fractions containing the objective compound were collected, evaporated under reduced pressure and treated with 4N hydrogen chloride in ethyl acetate solution to give 3-benzhydryl-1-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]piperazine dihydrochloride 25 (74 mg) as a colorless powder.

30

NMR (DMSO-d₆, δ): 2.60-4.81 (14H, m), 7.17-7.50 (11H, m), 7.22-7.75 (2H, m)

MASS (APCI): 509 (M+H)⁺(free)

35 Preparation 28

Sodium triacetoxyborohydride (146 mg) was added portionwise to a mixture of 37% aqueous formaldehyde (30 mg) and 3-benzhydryl-1-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]piperazine dihydrochloride in a mixture of dichloromethane (4 ml) and methanol (2 drops) at 0°C and the whole was stirred at 5°C - room temperature overnight. The mixture was partitioned between ethyl acetate and 2N sodium hydroxide. The organic layer was separated, washed with brine, dried over sodium sulfate and evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel using a mixed solvent of dichloromethane and methanol (60:1). The fractions containing the objective compound were collected and evaporated under reduced pressure and treated with 4N hydrogen chloride in ethyl acetate solution to give 2-benzhydryl-4-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-1-methylpiperazine dihydrochloride (32.9 mg) as a colorless powder.

NMR (DMSO-d₆, δ): 2.28-4.73 (16H, m), 7.15-7.40 (9H, m), 7.55 (2H, m), 7.71 (2H, m)

MASS (APCI): 523 (M+H)⁺(free)

20

Preparation 29

Lithium aluminum hydride (198 mg) was added by small portions to an ice-cooled solution of 1,4-dibenzyl-3-benzhydryl-2,5-piperazinedione (800 mg) in tetrahydrofuran (8 ml) under nitrogen atmosphere, and the mixture was stirred under reflux for 5 hours. After being cooled with ice, 2N sodium hydroxide (1 ml) was added to the mixture under nitrogen atmosphere. The resulting precipitates were filtered off and washed with tetrahydrofuran, and the filtrate and the washings were combined and evaporated under reduced pressure to give a crude oil. The oil was purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (9:1). The fractions containing the objective compound were collected, evaporated under reduced pressure and treated with 4N hydrogen chloride in ethyl acetate solution to give 1,4-dibenzyl-2-benzhydrylpiperazine dihydrochloride (846 mg) as a colorless powder.

NMR (DMSO- d_6 , δ): 2.30-6.50 (12H, m), 7.03-7.98 (20H, m)

MASS (APCI): 433 (M+H)⁺(free)

Preparation 30

5 (6R, 9aR)-6-Benzhydryl-8-(tert-butoxycarbonyl)-
octahydropyrazino[2,1-c][1,4]oxazine was treated with 4N hydrogen
chloride in 1,4-dioxane to give (6R, 9aR)-octahydro-6-
benzhydrylpyrazino[2,1-c][1,4]oxazine dihydrochloride as a yellowish
powder. (6R, 9aR)-6-Benzhydryl-8-[2-methoxy-5-[5-(trifluoromethyl)-
10 1H-tetrazol-1-yl]benzyl]octahydropyrazino[2,1-c][1,4]oxazine
dihydrochloride was obtained from (6R, 9aR)-6-
benzhydrylhexahydropyrazino[2,1-c][1,4]oxazine dihydrochloride
according to a similar manner to that of Example 2.

NMR (DMSO- d_6 , δ): 2.07-2.60 (3H, m), 2.75-4.54 (17H, m),

15 7.18-7.78 (13H, m)

MASS (APCI): 565 (M+H)⁺(free)

Preparation 31

Acetyl chloride (3 drops) was added to a mixture of (6R, 9aS)-
20 4-benzhydryl-2-(2-methoxybenzyl)octahydropyrazino[1,2-a]pyrazine
trihydrochloride (20 mg) and N,N-diisopropylethylamine (6 drops) in
dichloromethane (1 ml) under ice-cooling. After being stirred at
the same temperature for 2 hours, the mixture was poured into ice-
water and extracted with ethyl acetate. The extract was washed with
25 brine, dried over sodium sulfate and evaporated under reduced
pressure to give a crude oil. The oil was purified by column
chromatography on silica gel using a mixed solvent of
dichloromethane and methanol (50:1) as an eluent. The fractions
containing the objective compound were collected and evaporated
30 under reduced pressure and the resulting residue was treated with 4N
hydrogen chloride in ethyl acetate to give 1-[(6R, 9aR)-6-benzhydryl-
8-(2-methoxybenzyl)octahydropyrazino[1,2-a]pyrazin-2-yl]ethanone
dihydrochloride (9.8 mg) as a colorless powder.

NMR (DMSO- d_6 , δ): 1.90-4.60 (21H, m), 6.95-7.39 (14H, m)

35 MASS (APCI): 470 (M+H)⁺(free)

Example 1

The following compound was obtained according to a similar manner to that of Preparation 28.

5

2-[2-Benzhydryl-4-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-1-piperazinyl]acetic acid

MASS (APCI): 567 (M+H)⁺

10

Dihydrochloride of the above compound

IR (KBr, FT-IR): 1615, 1440, 1320, 1265, 1235 cm⁻¹

NMR (DMSO-d₆, δ): 2.70-5.15 (12H, m), 3.84 (3H, s), 7.10-8.10 (13H, m), 10.36 (1H, br s)

MASS (APCI): 567 (M+H)⁺(free)

15

Example 2

Thionyl chloride (0.5 ml) was added dropwise to an ice-cooled methanol (3 ml) over 15 minutes. The mixture was stirred for 15 minutes and thereto 2-[2-benzhydryl-4-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-1-piperazinyl]acetic acid (93 mg) was added. The whole mixture was stirred at room temperature overnight and evaporated under reduced pressure. The syrup was partitioned between aqueous sodium hydrogen carbonate and dichloromethane. The organic layer was separated, dried over magnesium sulfate and evaporated under reduced pressure. The syrup was purified by column chromatography on silica gel using a mixed solvent of dichloromethane and methanol (20:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give a syrup. The syrup was treated with 4N hydrogen chloride in ethyl acetate (1 ml) to give methyl 2-benzhydryl-4-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-1-piperazinyl]acetate dihydrochloride (44 mg).

20

25

30

35

IR (KBr, FT-IR): 1735, 1500, 1440, 1320, 1265 cm⁻¹

NMR (DMSO-d₆, δ): 1.93-4.65 (10H, m), 3.32 (3H, s), 3.46 (3H, s), 3.83 (2H, s), 6.98-8.25 (13H, m)

MASS (APCI): 581 (M+H)⁺(free)

Example 3

The following compound was obtained according to a similar
5 manner to that of Preparation 31.

1-Acetyl-2-benzhydryl-4-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]piperazine dihydrochloride

IR (KBr, FT-IR): 1655, 1635, 1440, 1415, 1320, 1265 cm⁻¹

10 NMR (DMSO-d₆, δ): 1.81 (3H, s), 2.65-5.60 (10H, m), 3.49 (3H, s), 7.05-8.15 (13H, m)

MASS (APCI): 551 (M+H)⁺(free)

Example 4

15 The following compounds were obtained according to a similar manner to that of Preparation 27 from (4R,8aS)-4-benzhydryloctahydropyrrolo[1,2-a]pyrazine dihydrochloride.

20 Benzyl [(4R,7S,8aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-7-yl]carbamate

MASS (APCI): 698 (M+H)⁺

Dihydrochloride of the above compound

25 IR (KBr): 2900-2500, 1716, 1504 cm⁻¹

NMR (CDCl₃, δ): 1.80-2.60 (14H, m), 2.86 (1H, d, J=10.2Hz),
3.20-3.32 (1H, m), 3.44 (1H, d, J=15.1Hz), 3.55 (1H, d, J=15.1Hz), 3.80 (3H, s), 3.95 (1H, d, J=8.5Hz), 4.95 (1H, d, J=8.6Hz), 5.04 (2H, s), 6.92 (1H, d, J=8.8Hz), 7.06-
30 7.34 (11H, m), 7.42 (1H, d, J=2.6Hz)

MASS (APCI): 698 (M+H)⁺(free)

Example 5

Sodium triacetoxymethylborohydride (163 mg) was added to a mixture
35 of bis(acetic acid) salt of (7R,8aS)-4-benzhydryl-7-[(tert-

butyldimethylsilyl)oxy]octahydropyrrolo[1,2-a]pyrazine (0.38 g) and 2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzaldehyde (210 mg) in dichloromethane, and the whole was stirred for 3 hours at room temperature. The mixture was washed with aqueous sodium hydrogen carbonate, dried over magnesium sulfate and concentrated under reduced pressure. The syrup was purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (4:1). The later eluting fractions were collected and evaporated under reduced pressure to give colorless oil of (4R,7R,8aS)-4-benzhydryl-7-[(tert-butyldimethylsilyl)oxy]-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazine (0.18 g).

NMR (CDCl₃, δ): -0.20 (3H, s), -0.11 (3H, m), 0.75 (9H, m), 1.58-1.74 (4H, m), 2.18 (1H, dd, J=4.7 and 9.6Hz), 2.26 (1H, dd, J=3.3 and 11.3Hz), 2.31 (1H, d, J=11.3Hz), 2.69 (1H, dd, J=3.0 and 10.6Hz), 2.96 (1H, dd, J=6.7 and 9.5Hz), 3.25 (1H, d, J=14.8Hz), 3.30-3.50 (1H, m), 3.69 (1H, d, J=10.6Hz), 3.87 (3H, s), 4.20-4.25 (1H, m), 4.66 (1H, d, J=10.8Hz), 6.94-7.40 (12H, m), 7.54 (1H, d, J=2.6Hz)

MASS (APCI-ES): 679 (M+H)⁺

The earlier eluting fractions were collected and evaporated under reduced pressure to give colorless oil of (4S,7R,8aS)-4-benzhydryl-7-[(tert-butyldimethylsilyl)oxy]-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazine (0.15 g).

NMR (CDCl₃, δ): -0.20 (3H, s), -0.11 (3H, m), 0.75 (9H, m), 1.56-1.95 (6H, m), 2.47 (1H, d, J=11.2Hz), 2.64-2.92 (2H, m), 3.36-3.60 (3H, m), 2.78 (3H, s), 3.92 (1H, d, J=11.1Hz), 4.07-4.17 (1H, m), 6.92 (1H, d, J=8.8Hz), 7.05-7.45 (12H, m)

MASS (APCI-ES): 679 (M+H)⁺(free)

The following compounds were obtained according to a similar manner to that of Preparation 30.

- (1) N-[(4R, 7S, 8aS)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-7-yl]acetamide dihydrochloride
IR (KBr): 3400, 1648, 1504 cm^{-1}
NMR (DMSO- d_6 , δ): 1.48 (1H, br s), 1.76 (3H, s), 2.30-5.00 (12H, m), 3.76 (3H, s), 7.16-7.77 (13H, m), 8.21 (1H, br s)
MASS (APCI): 606 (M+H)⁺(free)
- (2) (4R, 8aS)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]hexahydropyrrolo[1,2-a]pyrazin-7(6H)-one dihydrochloride
NMR (DMSO- d_6 , δ): 2.15-4.30 (17H, m), 7.18-8.08 (13H, m), 10.37 (1H, m)
MASS (APCI): 563 (M+H)⁺(free)
- (3) (4R, 8aS)-4-Benzhydryl-7,7-difluoro-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazine dihydrochloride
NMR (DMSO- d_6 , δ): 2.15-4.30 (17H, m), 7.20-7.85 (13H, m), 10.5 (1H, br)
MASS (APCI): 585 (M+H)⁺(free)
- (4) N-[(4R, 7R, 8aS)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-7-yl]acetamide dihydrochloride
NMR (DMSO- d_6 , δ): 1.80-4.55 (23H, m), 7.21-8.14 (13H, m)
MASS (APCI): 606 (M+H)⁺(free)
- (5) (4R, 7S, 8aS)-4-Benzhydryl-7-cyano-2-[2-methoxy-5-[5-

(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazine dihydrochloride
IR (KBr): 3435, 1506 cm^{-1}
NMR (DMSO-d_6 , δ): 2.20-4.30 (14H, m), 3.78 (3H, s), 7.21-7.84
5 (13H, m)
MASS (APCI-): 327 (M-H)

(6) (4R, 7S, 8aS)-4-Benzhydryl-7-carbamoyl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazine dihydrochloride
10 $[\alpha]_D^{25}$: -17.684 (C, 0.095, MeOH)
IR (KBr): 1684 cm^{-1}
NMR (DMSO-d_6 , δ): 2.20-4.80 (14H, m), 3.77 (3H, s), 7.06-7.74
(13H, m)
15 MASS (APCI): 592 (M+H)

(7) (4R, 8aS)-N-[4-Benzhydryl-2-[2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl)benzyl]octahydropyrrolo[1,2-a]pyrazin-7-yl]-2-hydroxyacetamide dihydrochloride
20 mp 155-159°C
 $[\alpha]_D^{28.3}$: -18.852 (c=0.061, MeOH)
IR (KBr): 3396, 1645, 1535, 1514, 1200, 1165 cm^{-1}
NMR (CDCl_3 , δ): 1.40-5.50 (19H, m), 6.80-8.10 (13H, m)
MASS (ES+): 622.3 (M+H)⁺, 644.2 (M+Na)⁺
25

Example 7

Acetic anhydride (18 mg) was added dropwise to an ice-cooled solution of (4R, 7S, 8aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-7-ol dihydrochloride (58.3 mg), and pyridine (36.2 mg) in
30 dichloromethane (1 ml). After being stirred at the same temperature for 2 hours, triethylamine (27.8 mg) was added to the mixture and the whole was stirred at room temperature overnight. The mixture was poured into ice-water and extracted with dichloromethane. The
35 extract was washed with brine, dried over sodium sulfate and

evaporated under reduced pressure to give a crude oil. The resulting residue was purified by preparative silica gel column chromatography with a mixture of hexane and ethyl acetate (1:2) as an eluent. The obtained oil was treated with 4N hydrogen chloride in ethyl acetate solution to give (4R,7S,8aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (57.6 mg).

NMR (DMSO- d_6 , δ): 1.40-4.87 (22H, m), 7.21-7.77 (13H, m)

10 MASS (APCI): 606 (M+H)⁺(free)

Preparation 32

To a solution of (2S)-2-[N-(2-methoxybenzyl)-N-(2-oxo-3,3-diphenylpropyl)amino]methyl]piperazine-1,4-dicarboxylic acid 4-N-benzyl ester 1-N-tert-butyl ester (3.15 g) in ethyl acetate (15 ml) was added a solution of 4N hydrogen chloride in ethyl acetate (29.6 ml) under ice-cooling. After stirring at the same temperature for 3 hours, the reaction mixture was evaporated under reduced pressure. To the solution of the residue in dichloromethane (30 ml) was added portionwise sodium triacetoxyborohydride (2.95 g) under ice-cooling, and then it was stirred at the same temperature for 20 hours. The mixture was poured into aqueous sodium hydrogen carbonate and extracted with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate, evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (5.2 g) using a mixed solvent of hexane and ethyl acetate (2:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give (4S,9aS)-8-(benzyloxycarbonyl)-4-benzhydryl-2-(2-methoxybenzyl)octahydro-2H-pyrazino[1,2-a]pyrazine (2.0 g) as a syrup.

NMR (CDCl₃, δ): 3.68 (3H, s), 1.75-4.25 (15H, m), 5.08 (2H, s), 6.70-6.90 (2H, m), 7.10-7.40 (17H, m)

MASS (APCI): 562 (M+H)⁺

35 Example 8

The following compound was obtained according to a similar manner to that of Preparation 8 from (4R,8S,8aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-8-ol.

5

(4R,8aR)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]hexahydropyrrolo[1,2-a]pyrazin-8(2H)-one dihydrochloride

NMR (DMSO-d₆, δ): 1.98-4.24 (18H, m), 7.21-7.80 (13H, m)

10

MASS (APCI): 563 (M+1) (free)

Example 9

The following compound was obtained according to a similar manner to that of Preparation 6 from (4R,8S,8aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-8-ol.

15

(4R,8R,8aR)-8-Azido-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazine

20

MASS (APCI): 590 (M+1)

Example 10

The following compound was obtained according to a similar manner to that of Preparation 7 from (4R,8R,8aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-8-amine.

25

N-[(4R,8R,8aR)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-8-yl]acetamide dihydrochloride

30

NMR (DMSO-d₆, δ): 1.23-4.30 (21H, m), 7.21-7.56 (13H, m)

MASS (APCI): 606 (M+1)

Example 11

35

The following compound was obtained according to a similar manner to that of Preparation 10 from (4R,8S,8aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-8-ol.

5

(4R, 8R, 8aR)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-8-yl acetate

NMR (CDCl₃, δ): 1.91-2.23 (5H, m), 2.03 (3H, s), 2.43 (2H, br),
2.63-2.89 (2H, m), 3.24 (1H, br), 3.42-3.64 (2H, d x 2,
J=15Hz), 3.78 (3H, s), 4.09 (1H, m), 5.18 (1H, m), 6.90-
7.42 (13H, m)

10

MASS (APCI) : 607 (M+1)

Example 12

15

The following compound was obtained according to a similar manner to that of Preparation 6 from (4R,8R,8aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-8-ol.

20

(4R,8S,8aR)-8-Azido-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazine

MASS (APCI): 590 (M+1) (free)

Example 13

25

The following compound was obtained according to a similar manner to that of Preparation 7 from (4R,8S,8aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-8-amine.

30

N-[(4R, 8S, 8aR)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-8-yl]acetamide dihydrochloride

NMR (DMSO-d₆, δ): 1.14-4.77 (23H, m), 6.82-8.16 (13H, m)

35

MASS (APCI): 606 (M+1)

Example 14

The following compounds were obtained according to a similar manner to that of Preparation 31.

5

- (1) (4R, 9aR)-8-Acetoxyacetyl-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride
mp: 138-153°C

10

$[\alpha]_D^{26}$: -39.70 (C, 0.11, MeOH)
IR (KBr): 1743, 1676, 1653 cm^{-1}
NMR (DMSO- d_6 , δ): 2.02 and 2.05 (total 3H, s), 2.20-4.80 (17H, m), 3.80 and 3.85 (total 3H, s), 7.18-7.80 (13H, m)
MASS (APCI+): 664.1 (M+H)⁺(free)

15

- (2) (4R, 9aR)-8-(2-Acetoxy-2-methylpropionyl)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride
mp: 143-148°C

20

IR (KBr): 1738, 1647 cm^{-1}
NMR (DMSO- d_6 , δ): 1.42 (3H, s), 1.45 (3H, s), 2.00 (3H, s), 2.20-4.40 (15H, m), 3.83 (3H, s), 7.18-7.90 (13H, m)
MASS (APCI+): 692.2 (M+H)⁺(free)

25

- (3) (4R, 9aR)-4-Benzhydryl-8-cyclohexanecarbonyl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride
mp: 169-174.5°C

30

$[\alpha]_D^{28}$: -36.40 (C, 0.125, MeOH)
IR (KBr): 1647 cm^{-1}
NMR (DMSO- d_6 , δ): 1.00-1.80 (10H, m), 2.20-4.40 (16H, m), 3.80 (3H, s), 7.14-7.81 (13H, m)
MASS (APCI+): 674.2 (M+H)⁺(free)

35

- (4) (4R, 9aR)-4-Benzhydryl-8-cyclopropanecarbonyl-2-[2-methoxy-5-[5-

(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

mp: 165-168°C

$[\alpha]_D^{30.0}$: -42.24° (C=0.29, MeOH)

5 IR (KBr): 3435, 1645, 1504, 1460, 1265, 1201, 1165, 1034 cm⁻¹

NMR (DMSO-d₆, δ): 0.65-0.82 (4H, m), 1.90-4.50 (16H, m), 3.81 (3H, s), 7.10-7.50 (11H, m), 7.70-7.90 (2H, m)

MASS (APCI): 632 (M+H)⁺(free)

10 (5) (4R, 9aR)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(3-pyridylcarbonyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride

mp: 197-200°C

$[\alpha]_D^{30.0}$: -42.46° (C=0.325, MeOH)

15 IR (KBr): 3404, 1649, 1504, 1458, 1269, 1199, 1165 cm⁻¹

NMR (DMSO-d₆, δ): 2.20-5.00 (15H, m), 3.80 (3H, s), 7.10-7.50 (11H, m), 7.70-7.95 (3H, m), 8.32 (1H, s), 8.86 (1H, dd, J=1.3Hz, J=5.4Hz), 8.92 (1H, s)

MASS (APCI): 668 (M)⁺(free)

20

(6) (4R, 9aR)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(trifluoroacetyl)octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

NMR (DMSO-d₆, δ): 2.30-4.25 (20H, m), 7.17-8.14 (13H, m)

25 MASS (APCI): 660 (M+H)⁺(free)

(7) (4R, 9aR)-4-Benzhydryl-8-(methoxyacetyl)-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

30 NMR (DMSO-d₆, δ): 2.21-4.28 (23H, m), 7.17-8.14 (13H, m), 10.24-10.27 (2H, m)

MASS (APCI): 636 (M+H)⁺(free)

(8) Methyl 3-[(6R, 9aR)-6-benzhydryl-8-[2-methoxy-5-(5-trifluoromethyl-1H-tetrazol-1-yl)benzyl]octahydro-2H-

35

pyrazino[1,2-a]pyrazin-2-yl]-3-oxopropanoate

IR (KBr): 1741, 1645 cm^{-1}

MASS (APCI): 664.07 (M+H)⁺(free)

5 Dihydrochloride of the above compound

IR (KBr): 1741, 1651 cm^{-1}

NMR (DMSO- d_6 , δ): 2.20-4.40 (23H, m), 7.21-7.90 (13H, m)

MASS (APCI⁺): 664.1 (M+H)⁺(free)

10 Example 15

To a solution of (4R,9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (120 mg) in dichloromethane (1.0 ml) were added N,N-diisopropylethylamine (0.186 ml) and
15 acetoxyacetyl chloride (28.8 μl) at 0°C. After stirring at 0°C for 1 hour, the mixture was quenched with aqueous saturated sodium hydrogen carbonate (15 ml) and extracted with dichloromethane (20 ml $\times 2$). The combined organic extracts were washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure to
20 give solid (123 mg). To a solution of the solid in methanol (2 ml) was added potassium carbonate (37 mg). After stirring at room temperature for 1 hour, the mixture was evaporated under reduced pressure. The residue was portioned between brine and dichloromethane. The organic layer was dried over magnesium sulfate
25 and evaporated under reduced pressure. The residue was purified with preparative TLC (methanol/chloroform = 1/19) to give an oil. To a solution of the oil in ethyl acetate (1 ml) was added 4N hydrogen chloride in ethyl acetate (0.5 ml) and hexane (20 ml). After stirring for 30 minutes, the precipitate was collected by
30 filtration and dried under reduced pressure at 50°C for 5 hours to give (4R,9aR)-4-benzhydryl-8-hydroxyacetyl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (96.3 mg) as a white solid.

mp: 140-159°C

35 $[\alpha]_D^{26}$: -46.03 (C, 0.105, MeOH)

IR (KBr): 1649, 1508 cm^{-1}

NMR (DMSO-d_6 , δ): 2.20-4.50 (17H, m), 3.82 (3H, s), 7.18-7.82 (13H, m)

MASS (APCI): 622 (M+H)⁺, 644 (M+Na)⁺

5

Example 16

The following compounds were obtained according to a similar manner to that of Example 15.

- 10 (1) (4R, 9aR)-4-Benzhydryl-8-(3-hydroxypropionyl)-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

mp: 147-154°C

$[\alpha]_D^{27}$: -34.67 (C, 0.125, MeOH)

15

IR (KBr): 1645 cm^{-1}

NMR (DMSO-d_6 , δ): 2.10-4.40 (19H, m), 3.82 (3H, s), 7.18-7.82 (13H, m)

MASS (APCI⁺): 635.9 (M+H)⁺(free)

- 20 (2) (4R, 9aR)-4-Benzhydryl-8-[(2S)-2-hydroxypropionyl]-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

mp: 150-158°C

$[\alpha]_D^{27}$: -31.33 (C, 0.125, MeOH)

25

IR (KBr): 1647 cm^{-1}

NMR (DMSO-d_6 , δ): 1.13 (3H, d, J=6.4Hz), 3.82 (3H, s), 2.00-4.40 (16H, m), 7.18-7.82 (13H, m)

MASS (APCI⁺): 635.87 (M+H)⁺(free)

- 30 (3) (4R, 9aR)-4-Benzhydryl-8-(2-hydroxy-2-methylpropionyl)-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

$[\alpha]_D^{27}$: -35.33 (C, 0.125, MeOH)

IR (KBr): 1647 cm^{-1}

35

NMR (DMSO-d_6 , δ): 1.26 (3H, s), 1.28 (3H, s), 2.20-4.40 (15H,

m), 3.80 (3H, s), 7.18-7.81 (13H, m)

MASS (APCI+): 650.1 (M+H)⁺(free)

Example 17

5 To a mixture of (4R,9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (80 mg), cyclopentanecarboxylic acid (16.9 μ l), 1-hydroxybenzotriazole hydrate (23 mg), and triethylamine (79 μ l) in dichloromethane (1 ml) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride at room
10 temperature. After stirring at room temperature overnight, the mixture was quenched with aqueous saturated sodium hydrogen carbonate and extracted with dichloromethane. The extract was dried over magnesium sulfate and evaporated under reduced pressure. The
15 residue was purified with preparative TLC (methanol/chloroform = 1/9) to give an oil. To a solution of the oil in ethyl acetate (1 ml) was added 4N hydrogen chloride in ethyl acetate (0.2 ml) and hexane (20 ml). After stirring for 30 minutes, the precipitate was collected by filtration and dried under reduced pressure at 50°C for
20 5 hours to give (4R,9aR)-4-benzhydryl-8-cyclopentanecarbonyl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (63.9 mg) as a powder.

mp: 170-178°C, decomp.

$[\alpha]_D^{25}$: -37.83 (C, 0.115, MeOH)

25 IR (KBr) 1647 cm^{-1}

NMR (DMSO- d_6 , δ): 1.40-1.80 (8H, m), 2.20-4.50 (16H, m), 3.80 and 3.82 (total 3H, s), 7.15-7.82 (13H, m)

MASS (APCI+): 660.2 (M+H)⁺(free)

30 Example 18

The following compounds were obtained according to a similar manner to that of Example 17.

(1) (4R,9aR)-4-Benzhydryl-8-cyclobutanecarbonyl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-
35

pyrazino[1,2-a]pyrazine dihydrochloride

mp: 155-167°C, decomp.

$[\alpha]_D^{27}$: -41.40 (C, 0.095, MeOH)

IR (KBr): 1647 cm^{-1}

5 NMR (DMSO- d_6 , δ): 1.60-4.40 (22H, m), 3.18 and 3.83 (total 3H, s), 7.18-7.82 (13H, m)

MASS (APCI+): 646.1 (M+H)⁺(free)

10 (2) (4R, 9aR)-4-Benzhydryl-8-(3-methoxypropionyl)-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

mp: 132-135°C

$[\alpha]_D^{27}$: -35.17 (C, 0.1, MeOH)

IR (KBr): 1649 cm^{-1}

15 NMR (DMSO- d_6 , δ): 2.20-4.40 (19H, m), 3.19 (3H, s), 3.80 and 3.83 (total 3H, s), 7.15-7.81 (13H, m)

MASS (APCI+): 650.1 (M+H)⁺(free)

20 (3) (4R, 9aR)-4-Benzhydryl-8-(3,3,3-trifluoropropionyl)-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

mp: 155-160°C

$[\alpha]_D^{26}$: -31.48 (C, 0.135, MeOH) *

IR (KBr): 1674 cm^{-1}

25 NMR (DMSO- d_6 , δ): 2.20-4.40 (17H, m), 3.80 and 3.84 (total 3H, m), 7.19-7.83 (13H, m)

MASS (APCI+): 674.1 (M+H)⁺(free)

Example 19

30 To a mixture of (4R, 9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (100 mg), 3-tert-butoxycarbonyl-3-azetidinecarboxylic acid (39.3 ml), 1-hydroxybenzotriazole hydrate (28.8 mg), and triethylamine (79 μ l) in dichloromethane (1 ml) was
35 added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride

(47.6 mg). After stirring at room temperature overnight, the mixture was quenched with aqueous saturated sodium hydrogen carbonate and extracted with dichloromethane. The extract was dried over sodium sulfate and evaporated under reduced pressure. The residue was purified with preparative TLC (methanol/chloroform = 1/9) to give an oil (101 mg). To a solution of the oil in a mixture of methanol and dioxane was added 4N hydrogen chloride in dioxane (0.27 ml). After stirring at room temperature overnight, the mixture was evaporated. The residue was added aqueous saturated sodium hydrogen carbonate and extracted with dichloromethane ($\times 3$). The organic extracts were dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified with preparative TLC (methanol/chloroform = 1/9) to give an oil (38 mg). To a solution of the oil in ethyl acetate (1 ml) were added 4N hydrogen chloride in ethyl acetate (0.2 ml) and hexane (20 ml). After stirring for 30 minutes, the precipitate was collected by filtration and dried under reduced pressure at 50°C for 5 hours to give (4R,9aR)-8-(3-azetidincarbonyl)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (39 mg) as a powder.

IR (KBr): 1651 cm^{-1}

NMR (DMSO- d_6 , δ): 2.20-4.40 (20H, m), 3.80 and 3.84 (total 3H, s), 7.10-7.79 (13H, m)

MASS (APCI+): 647.2 (M+H)⁺(free)

25

Example 20

To a solution of (4R,9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (100 mg) in N,N-dimethylformamide (1 ml) were added N,N-diisopropylethylamine (0.129 ml) and dimethylcarbonyl chloride (27.4 μl) at 0°C. After stirring at room temperature for 3 hours, the mixture was quenched with water and extracted with ethyl acetate ($\times 3$). The combined extracts were washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified with preparative TLC (methanol/chloroform =

35

1/19) to give an oil. To a solution of the oil in ethyl acetate (1 ml) were added a solution of 4N hydrogen chloride in ethyl acetate (0.5 ml) and hexane. The precipitate was collected by filtration and dried under reduced pressure for 5 hours at 50°C to give
5 (4R, 9aR)-4-benzhydryl-8-(dimethylcarbamoyl)-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (78.7 mg) as a white solid.

mp: 158-164°C

$[\alpha]_D^{27}$: -42.27 (C, 0.125, MeOH)

10 IR (KBr): 1647 cm^{-1}

NMR (DMSO- d_6 , δ): 2.20-4.50 (15H, m), 2.71 (6H, s), 3.80 (3H, s), 6.82-7.81 (13H, m)

MASS (APCI+): 634.9 (M+H)⁺(free)

15 Example 21

To a solution of (4R, 9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (100 mg) and N,N-diisopropylethylamine (80.2 μ l) in ethyl acetate (1 ml) was added methylisocyanate (2
20 drops). After stirring at room temperature for 1 hour, the mixture was quenched with water and extracted with ethyl acetate ($\times 3$). The combined extracts were washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified with preparative TLC (methanol/chloroform = 1/19) to give
25 an oil. To a solution of the oil in ethyl acetate (1 ml) were added 4N hydrogen chloride in ethyl acetate (0.5 ml) and hexane. The precipitate was collected by filtration and dried under reduced pressure for 5 hours at 50°C to give (4R, 9aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(methylethylcarbamoyl)octahydro-2H-pyrazino[1,2-a]pyrazine
30 dihydrochloride (88.7 mg) as a white solid.

mp: 160-170°C

$[\alpha]_D^{28}$: -30.27 (C, 0.125, MeOH)

IR (KBr): 1647 cm^{-1}

35 NMR (DMSO- d_6 , δ): 2.20-4.50 (18H, m), 3.81 (3H, s), 7.16-7.81

(13H, m)

MASS (APCI+): 620.9 (M+H)⁺(free)

Example 22

5 To a solution of (4R,9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (100 mg) in water (1 ml) and 1N hydrochloric acid (0.3 ml) was added a solution of sodium cyanate (19.3 mg) in water at room temperature, and the mixture was stirred
10 at room temperature for 2 hours. To the mixture was added a solution of sodium cyanate (20 mg) in water and 1N hydrochloric acid (0.3 ml) at room temperature, and the mixture was stirred overnight. To the mixture was added a solution of sodium cyanate (20 mg) in water and 1N hydrochloric acid (0.3 ml) at room temperature, and the
15 mixture was stirred for 2 hours. The mixture was diluted with water and extracted with dichloromethane. The organic extract was dried over sodium sulfate and evaporated under reduced pressure. The residue was purified with preparative TLC (methanol/chloroform = 1/19) to give an oil. To a solution of the oil in ethyl acetate (1
20 ml) were added a solution of 4N hydrogen chloride in ethyl acetate (0.5 ml) and hexane. The precipitate was collected by filtration and dried under reduced pressure for 5 hours at 50°C to give (4R,9aR)-4-benzhydryl-8-carbamoyl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (80 mg) as a white solid.

mp: 165-190°C

$[\alpha]_D^{25}$: -38.67 (C, 0.125, MeOH)

IR (KBr): 1653 cm⁻¹

NMR (DMSO-d₆, δ): 2.20-4.50 (15H, m), 3.81 (3H, s), 7.19-7.81

30 (13H, m)

MASS (APCI+): 606.9 (M+H)⁺(free)

Example 23

The following compound was obtained according to a similar
35 manner to that of Example 22.

[[(6R, 9aR) -6-Benzhydryl-8-[2-methoxy-5-(5-trifluoromethyl-1H-tetrazol-1-yl)benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]methylene]amine trihydrochloride

5 IR (KBr): 1707, 1647, 1512 cm^{-1}

NMR (DMSO-d_6 , δ): 2.20-4.40 (19H, m), 7.17-7.85 (13H, m)

MASS (APCI+): 591.0 (M+H)⁺(free)

Example 24

10 To a solution of (4R, 9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (100 mg) in ethanol (1 ml) were added methylacetimidate hydrochloride (12 mg) and N,N-diisopropylethylamine (91 μl) at room temperature, and the mixture
15 was allowed to stand at room temperature overnight. To the mixture was added 4N hydrogen chloride in ethyl acetate (0.2 ml), and the mixture was evaporated under reduced pressure. The residue was purified with preparative TLC (methanol/dichloromethane = 3/17). The elution was added 4N hydrogen chloride in ethyl acetate,
20 evaporated under reduced pressure, and dried under reduced pressure for 2 hours at 50°C to give [1-[(6R, 9aR)-6-benzhydryl-8-[2-methoxy-5-(5-trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]ethylidene]amine trihydrochloride (85.2 mg) as a white solid.

25 mp: 191-202°C

$[\alpha]_D^{26}$: -41.67 (C, 0.14, MeOH)

IR (KBr): 1682, 1620 cm^{-1}

NMR (DMSO-d_6 , δ): 2.21 and 2.27 (total 3H, s), 3.84(3H, brs),
2.20-4.40 (15H, m), 7.18-7.88 (13H, m)

30 MASS (APCI+): 605.1 (M+H)⁺(free)

Example 25

The following compounds were obtained according to a similar manner to that of Preparation 28.

(1) (4R, 9aS)-4-Benzhydryl-8-(cyclopropylmethyl)-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride

NMR (DMSO- d_6 , δ): 0.29-0.36 (2H, m), 0.57-0.61 (2H, m), 1.06 (1H, m), 2.40-4.58 (21H, m), 7.16-7.91 (13H, m), 10.99-11.63 (2H, m)

MASS (APCI): 618 (M+H)⁺(free)

(2) (4R, 9aR)-4-Benzhydryl-8-cyclobutyl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride

mp: 184-187°C

$[\alpha]_D^{30.0}$: -33.50° (C=1.00, MeOH)

IR (KBr): 3404, 1504, 1450, 1265, 1201, 1163 cm^{-1}

NMR (DMSO- d_6 , δ): 1.50-4.65 (22H, m), 3.82 (3H, s), 7.10-7.50 (11H, m), 7.70-7.95 (2H, m)

MASS (API-ES): 618 (M+H)⁺(free)

Example 26

A solution of (4R, 9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine (150 mg), 3-bromopyridine (42 mg), sodium tert-butoxide (36 mg), tris(dibenzylideneacetone)dipalladium (0) (4.9 mg), and (+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (1.7 mg) in toluene (3 ml) was stirred at room temperature for 10 minutes, followed by 80°C for 20 hours. After 3-bromopyridine (0.010 ml) and sodium tert-butoxide (14 mg) were added to the solution, the whole was stirred at 80°C for 2 hours. After being cooled to room temperature, the reaction mixture was poured into water, and extracted with ethyl acetate, and while the aqueous layer was adjusted to pH 9 with aqueous sodium bicarbonate. The extract was dried over sodium sulfate. After removal of solvent by evaporation, the resulting residue was purified by column chromatography on silica gel (8 g) using a mixed solvent of dichloromethane and methanol (35:1). The fractions containing the objective compound were collected and

evaporated under reduced pressure to give a syrup. To a solution of the syrup in dichloromethane (3 ml) was added a solution of 4N hydrogenchloride in ethyl acetate (0.25 ml), and triturated with diisopropyl ether. The precipitate was collected by filtration and
5 dried under reduced pressure for 5 hours at 40°C to give (4R,9aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(3-pyridyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (62 mg) as light brown powder.

mp: 175-178°C

10 IR (KBr): 3398, 1554, 1510, 1267, 1198, 1163 cm⁻¹

NMR (DMSO-d₆, δ): 2.20-4.60 (15H, m), 3.81 (3H, s), 7.10-7.50 (11H, m), 7.70-7.90 (3H, m), 8.06 (1H, d, J=8.9Hz), 8.20 (1H, d, J=5.2Hz), 8.44 (1H, s)

MASS (APCI): 641 (M+H)⁺(free)

15

Example 27

To a solution of chlorosulfonyl isocyanate (37.4 μl) in dichloromethane (1 ml) was added benzylalcohol (44.4 μl) under 5°C. After the mixture was stirred at the same temperature for 90 minutes
20 under 5°C, and thereto a solution of (4R,9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine (220 mg) and triethylamine (0.11 ml) in dichloromethane (1.5 ml) was added dropwise. The whole mixture was stirred at room temperature for 20 hours. After removal of solvent
25 by evaporation, the resulting residue was purified by column chromatography on silica gel (8 g) using a mixed solvent of dichloromethane and methanol (40:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give a syrup. A solution of the syrup in mixed solvents
30 of tetrahydrofuran (3 ml) and methanol (3 ml) was hydrogenated over 10% palladium-charcoal (50% wet, 90 mg) at room temperature under atmospheric pressure for 40 minutes. After removal of the catalyst by filtration, the filtrate was evaporated under reduced pressure. The resulting residue was purified by column chromatography on
35 silica gel (7 g) using a mixed solvent of dichloromethane and

methanol (35:1). The fractions containing the objective compound were collected and evaporated under reduced pressure. To the residue was added a solution of 4N hydrogen chloride in ethyl acetate (0.10 ml), and triturated with diisopropyl ether. The resulting precipitate was collected by filtration and dried under reduced pressure for 5 hours at 40°C to give (4R,9aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-sulfamoyloctahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (95 mg) as a colorless powder.

mp: 174-176°C
[α]_D^{20.0}: -39.15° (C = 0.295, MeOH)
IR (KBr): 3398, 1506, 1458, 1369, 1267, 1201, 1165 cm⁻¹
NMR (DMSO-d₆, δ): 2.10-4.50 (15H, m), 3.84 (3H, s), 6.77 (2H, s), 7.10-7.50 (11H, m), 7.70-7.90 (2H, m)
MASS (API-ES): 643 (M+H)⁺(free)

Example 28

To an ice-cooled solution of (4R,9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine (0.3 g), tert-butoxycarbonylglycine (93 mg), 1-hydroxybenzotriazole (72 mg) and triethylamine (0.11 ml) in dichloromethane (25 ml) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride. After the mixture was stirred for 5 hours at room temperature, additional tert-butoxycarbonylglycine (20 mg), 1-hydroxybenzotriazole (20 mg), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (25 mg) were added to the mixture. The mixture was stirred further for 15 hours and washed with aqueous sodium carbonate solution, the dichloromethane layer was separated, dried over magnesium sulfate and concentrated under reduced pressure. The syrup was purified by column chromatography on silica gel using a mixed solvent of dichloromethane and methanol (20:1). The fractions containing the objective compound were collected and evaporated under reduced pressure. The resulting syrup was dissolved into ethyl acetate (8 ml) and treated with 4N hydrogen chloride in ethyl acetate (1 ml).

After being stirred for 2 hours at room temperature diisopropyl ether (20 ml) was added to the mixture. The resulting precipitate was collected by filtration and washed with diisopropyl ether, dried in vacuo to give white powders of [2-[(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethyl]amine trihydrochloride (0.38 g).

IR (KBr): 3400, 2800-2500, 1533 cm^{-1}

NMR (DMSO-d_6 , δ): 2.10-4.80 (20H, m), 7.19-7.37 (10H, m),

10 7.77-7.81 (3H, m), 8.19-8.40 (5H, m)

MASS (APCI): 621 ($\text{M}+\text{H}$)⁺, 643 ($\text{M}+\text{Na}$) (free)

Example 29

The following compound was obtained according to a similar manner to that of Preparation 7.

(4R,9aR)-8-[(Acetylamino)acetyl]-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

20 IR (KBr): 1651, 1512 cm^{-1}

NMR (DMSO-d_6 , δ): 1.80 and 1.84 (total 3H, s), 2.20-4.30 (18H, m), 7.18-7.96 (13H, m)

MASS (APCI⁺): 662.93 ($\text{M}+\text{H}$)⁺

25 Example 30

The following compound was obtained according to a similar manner to that of Preparation 31.

(4R,9aR)-4-Benzhydryl-8-[[(benzyloxyacetyl) amino]acetyl]-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine

30 NMR (CDCl_3 , δ): 1.85-2.20 (4H, m), 2.40-3.57 (10H, m), 3.82

(3H, d, $J=3.9\text{Hz}$), 3.99 (2H, s), 3.98-4.21 (3H, m), 4.59

(2H, s), 6.91-7.53 (18H, m)

35 MASS (ESI⁺): 769.2 ($\text{M}+\text{H}$)⁺, 791.3 ($\text{M}+\text{Na}$)

Example 31

To a solution of (4R,9aR)-4-benzhydryl-8-
[[(benzyloxyacetyl) amino] acetyl]-2-[2-methoxy-5-[5-
5 (trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-
a]pyrazine (39 mg) in methanol (15 ml) were added palladium on
carbon (10 mg) and concentrated hydrochloric acid (8 ml). After
stirring at room temperature under hydrogen for 5 hours, the mixture
was filtered. The filtrate was evaporated and purified with
10 preparative TLC (methanol/chloroform =1/9) to give an oil. The oil
was added 4N hydrogen chloride in ethyl acetate (0.5 ml), evaporated,
dried under reduced pressure at 50°C for 5 hours to give (4R,9aR)-4-
benzhydryl-8-[[(hydroxyacetyl) amino] acetyl]-2-[2-methoxy-5-[5-
(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-
15 a]pyrazine dihydrochloride as a white powder (26.3 mg).

IR (KBr): 1684, 1649 cm^{-1}

NMR (DMSO- d_6 , δ): 2.20-4.40 (19H, m), 3.81 and 3.83 (total 3H,
s), 7.10-7.78 (13H, m)

MASS (ESI+): 679.3 (M+H)⁺, 701.2 (M+Na)

20

Example 32

To a solution of (0.5 g) and triethylamine (0.31 ml) in
tetrahydrofuran (10 ml) was added methyl bromoacetate (136 mg)
dropwise over 10 minutes, under ice-cooling, and the mixture was
25 stirred at room temperature for 5 hours. The mixture was washed
with sodium carbonate aqueous solution, dried over magnesium sulfate
and concentrated under reduced pressure. The residue was purified
by column chromatography on silica gel using a mixed solvent of
dichloromethane and methanol. The fractions containing the
30 objective compound were collected and concentrated under reduced
pressure to give methyl [(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-[5-
(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-
a]pyrazin-2-yl]acetate (0.46 g) as an oil.

NMR (CDCl₃, δ): 1.95-2.25 (5H, m), 2.41 (1H, d, J=11.2Hz),
35 2.60-2.80 (4H, m), 2.83 (1H, d, J=10.7Hz), 3.11 (2H, s),

3.26-3.40 (1H, m), 3.37 (1H, d, J=15.0Hz), 3.50 (1H, d, J=15.0Hz), 3.68 (3H, s), 3.80 (3H, s), 4.18 (1H, d, J=7.2Hz), 6.92 (1H, d, J=8.7Hz), 7.06-7.30 (11H, m), 7.38 (1H, d, J=2.6Hz)

5 MASS (APCI): 636 (M+H)⁺

Trihydrochloride of the above compound

IR (KBr): 3400, 2800-2500, 1533 cm⁻¹

10 NMR (DMSO-d₆, δ): 2.50-5.00 (17H, m), 3.71 (3H, s), 3.81 (3H, s), 7.24-7.33 (11H, m), 7.80-7.85 (2H, m)

MASS (APCI): 636 (M+H)⁺(free)

Example 33

The mixture of methyl [(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-
15 [5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]acetate (0.14 g) and 20% ammonia in methanol was allowed to stand in sealed vessel for 2 days. After removal of solvent, the residue was dissolved into ethyl acetate (5 ml) and thereto 4N hydrogen chloride in ethyl acetate (1 ml) was
20 added. Diisopropyl ether (10 ml) was added to the mixture, and the resulting precipitate was collected by filtration, washed with diisopropyl ether and dried in vacuo to give white powders of 2-[(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]acetamide trihydrochloride (0.14 g).
25

IR (KBr): 3400, 2800-2500, 1533 cm⁻¹

NMR (DMSO-d₆, δ): 2.10-4.80 (20H, m), 7.20-8.04 (13H, m), 8.64-9.03 (2H, m)

MASS (APCI): 621 (M+H)⁺ (free)

30

Example 34

The solution of methyl [(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-
[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]acetate (0.14 g) and 2M dimethylamine in
35 tetrahydrofuran (10 ml) was stirred in sealed tube at 40°C for 2

days. The mixture was concentrated under reduced pressure. The syrup was purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (4:1). The fractions containing the objective compound were collected and concentrated.

- 5 The resulting syrup was dissolved into ethyl acetate (8 ml) and treated with 4N hydrogen chloride in ethyl acetate to give 2-[(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-N,N-dimethylacetamide trihydrochloride (12 mg).

10 NMR (DMSO- d_6 , δ): 2.10-4.80 (17H, m), 2.87 (3H, s), 2.89 (3H, s), 3.80 (3H, s), 7.23-7.30 (10H, m), 7.77-7.81 (2H, m), 10.0-12.00 (3H, m)

MASS (APCI): 649 (M+H)⁺ (free)

15 Example 35

The following compound was obtained according to a similar manner to that of Example 32.

(4R,9aR)-4-Benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(2-oxopropyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride

20

mp: 175-179°C

$[\alpha]_D^{30.0}$: -43.07° (C=0.70, MeOH)

IR (KBr): 3425, 1728, 1506, 1450, 1267, 1199, 1163 cm^{-1}

25 NMR (DMSO- d_6 , δ): 2.14 (3H, s), 3.80 (3H, s), 2.20-4.70 (17H, m), 7.10-7.50 (11H, m), 7.70-7.90 (2H, m)

MASS (APCI): 620 (M+H)⁺ (free)

Example 36

- 30 A solution of methyl 3-[(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-(5-trifluoromethyl-1H-tetrazol-1-yl)benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-3-oxopropanoate (80 mg) and potassium carbonate (25 mg) in methanol (1 ml) was stirred at room temperature for 2.5 hours. The mixture was quenched with aqueous saturated ammonium chloride, and the whole solution was evaporated under
- 35

reduced pressure. The residue was added to dichloromethane and filtered. The filtrate was evaporated to give 3-[(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-(5-trifluoromethyl-1H-tetrazol-1-yl)benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-3-oxopropanoic acid (68 mg) as an oil.

MASS (APCI): 648.87 (M+H)⁺

Example 37

To a solution of 3-[(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-(5-trifluoromethyl-1H-tetrazol-1-yl)benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-3-oxopropanoic acid (68 mg), 2M dimethylamine in tetrahydrofuran (78.5 μ l), 1-hydroxybenzotriazole hydrate (17 mg) and triethylamine (58.4 μ l) in dichloromethane (1 ml) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (28 mg) at room temperature. After stirring at room temperature overnight, the mixture was quenched with aqueous saturated sodium hydrogen carbonate and extracted with dichloromethane (\times 3). The combined organic extracts were dried over sodium sulfate and evaporated under reduced pressure. The residue was purified with preparative TLC (methanol/chloroform = 1/9) to give an oil (60 mg). To a solution of the oil in ethyl acetate was added 4N hydrogen chloride in ethyl acetate (0.5 ml). The mixture was evaporated, and dried under reduced pressure at 50°C for 5 hours to give 2-[(6R,9aR)-6-benzhydryl-8-[2-methoxy-5-(5-trifluoromethyl-1H-tetrazol-1-yl)benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-3-oxopropanoic acid N,N-dimethylamide dihydrochloride (57.1 mg) as a powder.

mp: 155-168°C

$[\alpha]_D^{26}$: -25.90 (C, 0.13, MeOH)

IR (KBr): 1647 cm^{-1}

NMR (DMSO-d₆, δ): 2.20-4.40 (23H, m), 3.81 (3H, s), 7.10-7.90 (13H, m).

MASS (APCI⁺): 677.2 (M+H)⁺(free)

Example 38

To a suspension of 1-tert-butoxycarbonylamino-1-

cyclopropanecarboxylic acid (71.4 mg), (4R, 9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine (200 mg) in dichloromethane (3 ml) were added triethylamine (74.2 μ l) and 2-chloro-1-methylpyridinium iodide (136 mg) at room temperature. After being stirred for 3 hours, triethylamine (15 μ l) and 2-chloro-1-methylpyridinium iodide (27 mg) were added to the solution at the same temperature, and the whole was stirred at room temperature 20 hours. The solution was poured into aqueous saturated sodium hydrogen carbonate, and extracted with dichloromethane. The organic layer was separated, washed brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (6 g) using a mixed solvent of dichloromethane and methanol (40:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give a syrup. To a solution of the syrup in dichloromethane (3 ml) was added a solution of 4N hydrogen chloride in ethyl acetate (1.5 ml) under ice-cooling. After the mixture was stirred at room temperature for 2 hours, the solvent was removed by evaporation under reduced pressure. The residue was partitioned between aqueous saturated sodium hydrogen carbonate and dichloromethane, and the organic layer was separated, and dried over sodium sulfate. After removal of the solvent by evaporation, the resulting residue was purified by column chromatography on silica gel (4 g) using a mixed solvent of dichloromethane and methanol (25:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give a syrup. To a solution of the syrup in dichloromethane (2 ml) was added a solution of 4N hydrogen chloride in ethyl acetate (0.20 ml), and triturated with diisopropyl ether. The precipitate was collected by filtration and dried under reduced pressure for 5 hours at 40°C to give (4R, 9aR)-8-(1-amino-1-cyclopropanecarbonyl)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (63 mg) as a colourless powder.

IR (KBr): 3433, 2925, 1647, 1504, 1450, 1269, 1203, 1165 cm^{-1}

NMR (DMSO- d_6 , δ): 1.10-1.35 (4H, m), 3.81 (3H, s), 2.20-4.50 (15H, m), 7.10-7.50 (11H, m), 7.70-7.90 (2H, m), 9.06 (3H, s)

MASS (APCI): 647 (M+H)⁺(free)

5

Example 39

To a suspension of 1-[(tert-butyldimethylsilyloxy)methyl]-1-cyclopropanecarboxylic acid (81.8 mg) and (4R,9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-
10 octahydro-2H-pyrazino[1,2-a]pyrazine (200 mg) in dichloromethane (3 ml) were added triethylamine (74.2 μ l) and 2-chloro-1-methylpyridinium iodide (136 mg) at room temperature. After being stirred for 20 hours, the solution was poured into saturated sodium hydrogen carbonate solution, and extracted with dichloromethane.
15 The organic layer was separated, washed brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (6 g) using a mixed solvent of dichloromethane and methanol (60:1). The fractions containing the objective compound were collected and evaporated
20 under reduced pressure to give a syrup (32 mg). To a solution of the syrup in tetrahydrofuran (1 ml) was added tetrabutylammonium fluoride (24 μ l) was added under ice-cooling, and the whole was stirred at room temperature for 90 minutes. The reaction mixture was partitioned between water and ethyl acetate, and the organic
25 layer was washed brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative TLC using a mixed solvent of dichloromethane and methanol (20:1). The bands of silica gel containing the objective compound were collected, and extracted with dichloromethane and methanol (20:1). The extract
30 was evaporated under reduced pressure to give a syrup (10 mg). To a solution of the syrup in dichloromethane (1 ml) was added a solution of 4N hydrogen chloride in ethyl acetate (10 μ l), and triturated with diisopropyl ether. The precipitate was collected by filtration and dried under reduced pressure for 5 hours at 40°C to give
35 (4R,9aR)-4-benzhydryl-8-(1-hydroxymethyl-1-cyclopropanecarbonyl)-2-

[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (11 mg) as colorless powder.

IR (KBr): 3398, 1639, 1506, 1460, 1433, 1265, 1199, 1165, 1041
cm⁻¹

NMR (DMSO-d₆, δ): 0.60-1.30 (4H, m), 3.81 (3H, s), 2.20-4.50 (18H, m), 7.10-7.50 (11H, m), 7.70-7.90 (2H, m)

MASS (APCI): 662 (M+H)⁺(free)

10 Example 40

The following compound was obtained according to a similar manner to that of Example 17.

(4R, 9aR)-4-Benzhydryl-8-[(2S)-2-[(tert-butyl)diphenylsilyl]oxy]propionyl]-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine

NMR (CDCl₃, δ): 1.04 (9H, s), 1.28 (3H, d, J=4.7Hz), 1.80-2.05 (2H, m), 2.20-7.70 (12H, m), 3.81 (3H, s), 3.80-4.20 (2H, m), 4.38-4.55 (1H, m), 6.90-8.11 (23H, m)

MASS (APCI⁺): 874.3 (M+H)⁺, 896.4 (M+Na)

Example 41

To a solution of (4R, 9aR)-4-benzhydryl-8-[(2S)-2-[(tert-butyl)diphenylsilyl]oxy]propionyl]-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine (99.6 mg) in tetrahydrofuran (1.2 ml) were added acetic acid (0.02 ml) and tetrabutylammonium fluoride (1M tetrahydrofuran solution, 0.34 ml) at room temperature. After stirring at room temperature for 6 hours, the mixture was evaporated and purified with preparative TLC (ethyl acetate) to give an oil (78 mg). To a solution of the oil in ethyl acetate (1 ml) was added 4N hydrogen chloride in ethyl acetate (0.5 ml) and hexane (20 ml). After stirring for 30 minutes, the precipitate was collected by filtration and dried under reduced pressure at 50°C for 5 hours to give

(4R, 9aR)-4-benzhydryl-8-[(2R)-2-hydroxypropionyl]-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (68.6 mg) as a white solid.

IR(KBr): 1651 cm^{-1}

5 NMR (DMSO- d_6 , δ): 2.20-4.40 (19H, m), 7.18-7.82 (13H, m)

MASS (APCI+): 636.00 (M+H)⁺

Example. 42

To a suspension of 1-acetylamino-1-cyclopropanecarboxylic acid
10 (31.7 mg) in dichloromethane (3 ml) were added triethylamine (46.4 μl) and 2-chloro-1-methylpyridinium iodide (85 mg) at room temperature. After being stirred for 30 minutes, (4R, 9aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine (125 mg) was added to
15 the solution at the same temperature, and the whole was stirred at room temperature for 14 hours. After removal of solvent by evaporation, to the resulting residue were added N,N-dimethylformamide (3.5 ml) and triethylamine (15 μl), and the whole mixture was heated at 90°C for 3 hours with stirring. The solution
20 was partitioned between ethyl acetate and water, while aqueous layer was adjusted at pH 9 with aqueous saturated sodium hydrogen carbonate. The organic layer was separated, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by column chromatography on
25 silica gel (6 g) using a mixed solvent of toluene and ethyl acetate (35:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give a syrup. To a solution of the syrup in dichloromethane (3 ml) was added a solution of 4N hydrogen chloride in ethyl acetate (50 μl), and
30 triturated with diisopropyl ether. The precipitate was collected by filtration and dried under reduced pressure for 5 hours at 40°C to give (4R, 9aR)-8-(1-acetylamino-1-cyclopropanecarbonyl)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (47
35 mg) as colorless powder.

IR (KBr): 3435, 1658, 1649, 1506, 1450, 1265, 1201, 1163 cm^{-1}

NMR (DMSO-d_6 , δ): 0.70-0.90 (2H, m), 1.00-1.20 (2H, m), 1.73 (3H, s), 3.82 (3H, s), 2.10-4.50 (15H, m), 7.10-7.50 (11H, m), 7.70-7.90 (2H, m), 8.51 (1H, s)

5 MASS (APCI): 689 (M+H)⁺(free)

Preparation 33

Methanesulfonyl chloride (22.1 mg) was added to a mixture of (4R, 9aS)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride (100 mg) and N,N-diisopropylethylamine (116 μl) in dichloromethane under ice-cooling. After being stirred at the same temperature for 2 hours the mixture was poured into ice-water and extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulphate, and evaporated under reduced pressure. The resulting oil was purified by column chromatography on silica gel using a mixed solvent of dichloromethane and methanol. The fractions containing the objective compound was collected and evaporated under reduced pressure and the resulting residue was treated with 4N hydrogen chloride in ethyl acetate to give (4R, 9aR)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(methylsulfonyl)octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (52.8 mg) as colourless powder.

NMR (DMSO-d_6 , δ): 2.49-4.31 (23H, m), 7.17-7.80 (13H, m)

25 MASS: (APCI): 642 (M+H)⁺(free)

Example 43

The following compounds were obtained according to a similar manner to that of Preparation 33.

30

(1) (4R, 9aR)-4-Benzhydryl-8-dimethylsulfamoyl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

mp: 148-152°C

35 $[\alpha]_D^{30.0}$: -47.80° (C=0.41, MeOH)

IR (KBr): 3435, 1506, 1458, 1329, 1267, 1199, 1157 cm^{-1}

NMR (DMSO-d_6 , δ): 2.20-4.50 (15H, m), 2.72 (6H, s), 3.84 (3H, s), 7.10-7.50 (11H, m), 7.70-7.90 (2H, m)

MASS (APCI): 671 (M+H)⁺(free)

5

(2) (4R,9aR)-4-Benzhydryl-8-[(methanesulfonyl)methanesulfonyl]-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride
mp: 162-168°C

10 $[\alpha]_D^{30.0}$: -41.13° (C=0.80, MeOH)

IR (KBr): 1506, 1458, 1362, 1321, 1165 cm^{-1}

NMR (DMSO-d_6 , δ): 3.13 (3H, s), 2.20-4.50 (15H, m), 3.85 (3H, s), 5.25 (2H, s), 7.10-7.50 (11H, m), 7.70-7.90 (2H, m)

MASS (API-ES): 720 (M+H)⁺(free)

15

(3) (4R,9aR)-4-Benzhydryl-8-(2-hydroxyethanesulfonyl)-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine
MASS (APCI+) 671.9 (M+H)⁺

20

Dihydrochloride of the above compound

IR (KBr): 1512 cm^{-1}

NMR (DMSO-d_6 , δ): 2.20-4.40 (19H, m), 3.84 (3H, s), 7.10-7.85 (13H, m)

25

MASS (APCI+): 672.0 (M+H)⁺(free)

Example 44

To a solution of (4R,9aR)-4-benzhydryl-8-(2-hydroxyethanesulfonyl)-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine (16.2 mg)
30 in dichloromethane (1 ml) were added N,N-diisopropylethylamine (8.4 μl) and acetyl chloride (2.6 μl) at room temperature. After stirring for 1 hour, the mixture was quenched with aqueous saturated sodium hydrogen carbonate (10 ml) at 0°C and extracted with
35 dichloromethane (10 ml \times 2). The combined organic extracts were

washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified with preparative TLC (methanol/dichloromethane = 1/19) to give colorless oil (13.7 mg). To a solution of the oil in ethyl acetate (1 ml) was added 4N
5 hydrogen chloride in ethyl acetate (0.1 ml), and the mixture was evaporated under reduced pressure to give (4R,9aR)-8-(2-acetoxyethanesulfonyl)-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride (10 mg) as a white solid.

10 IR (KBr): 1741 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ): 1.96 (3H, s), 2.20-4.40 (19H, m), 3.84 (3H, s), 7.16-7.83 (13H, m)

MASS (APCI+): 714.3 (M+H)⁺, 736.2 (M+Na) (free)

15 Preparation 34

Diisopropylethylamine (0.236 ml) was added to an ice-cooled solution of 1-[3-(bromomethyl)-4-fluorophenyl]-5-(trifluoromethyl)-1H-tetrazole and in N,N-dimethylformamide (2 ml) and the mixture was stirred for 3 hours at room temperature. The mixture was washed
20 with aqueous sodium hydrogen carbonate. The organic layer was separated, dried over magnesium sulfate, and evaporated under reduced pressure. The syrup was purified by column chromatography on silica gel using a mixed solvent of dichloromethane and methanol (100:1 - 40:1). The fractions containing the objective compound
25 were collected to give a syrup. The syrup was treated with 4N hydrogen chloride in ethyl acetate solution to give (4R,8aS)-4-benzhydryl-2-[2-fluoro-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazine dihydrochloride (0.22 g).

IR (KBr): 3400, 2800-2500, 1533 cm^{-1}

30 NMR ($\text{DMSO}-d_6$, δ): 1.50-5.00 (13H, m), 7.15-8.00 (13H, m), 11.50-12.00 (2H, m)

MASS (APCI): 537 (M+H)⁺ (free)

Example 45

35 The following compound was obtained according to a similar

manner to that of Preparation 27.

(6R, 9aR)-6-Benzhydryl-8-[2-methoxy-5-(5-trifluoromethyl)-
tetrazol-1-yl]benzyl]octahydropyrazino[2,1-c][1,4]thiazine
5 dihydrochloride

mp 156-166°C

$[\alpha]_D^{28.8}$: -57.252 (c=0.131, MeOH)

IR (KBr): 3438, 2757-1936, 1508, 1200, 1163 cm^{-1}

NMR (DMSO- d_6 , δ): 1.60-4.70 (18H, m), 6.64-7.90 (13H, m), +D₂O

10 MASS (APCI): 581 (M+H)⁺

Example 46

Benzyl 3-oxopropylcarbamate (0.72 g; purity 70-80%; ref; J.
Chem. Soc. Chem. Comm., 8, 568 (1988)) and methyl (2R)-6-benzhydryl-
15 4-(2-methoxybenzyl)-2-piperazinecarboxylate (1 g) in tetrahydrofuran
(10 ml) were dissolved in a mixture of dichloromethane (10 ml) and
acetic acid (280 mg). The whole was stirred for 2 hours at room
temperature and thereto sodium triacetoxyborohydride (0.74 g) was
added and then the whole was stirred further for 20 hours. The
20 reaction mixture was washed with aqueous saturated sodium carbonate,
and the organic layer was dried over magnesium sulfate, and
evaporated under reduced pressure. The syrup was purified by column
chromatography on silica gel using a mixed solvent of hexane and
ethyl acetate (3:1). The main fractions were collected and
25 evaporated under reduced pressure to give methyl (2R)-6-benzhydryl-
1-[3-[(benzyloxy)carbonyl]amino]propyl]-4-(2-methoxybenzyl)-2-
piperazinecarboxylate containing the starting material.

MASS (APCI): 622 (M+H)⁺, 431

30 Example 47

A mixture of methyl (2R)-6-benzhydryl-1-[3-
[[(benzyloxy)carbonyl]amino]propyl]-4-(2-methoxybenzyl)-2-
piperazinecarboxylate (0.59 g), 10% palladium-charcoal (50% wet, 40
mg) and acetic acid (0.12 ml) in methanol (56 ml) was hydrogenated
35 under 3 atoms for 7.5 hours. After removal of solvent, the

resulting syrup was dissolved into dichloromethane (10 ml) and then triethylamine (0.47 ml), and di-tert-butyl dicarbonate (0.5 g) were added to the solution under ice-cooling. After being stirred for 1 hour, the mixture was washed with aqueous sodium carbonate, dried
5 over magnesium sulfate, and evaporated under reduced pressure. The syrup was purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (4:1). The main fractions were collected and evaporated under reduced pressure to give methyl (2R)-6-benzhydryl-1-[3-[[(tert-butoxy) carbonyl] amino]propyl]-4-(2-
10 methoxybenzyl)-2-piperazinecarboxylate. This compound was dissolved in dichloromethane and the solution was treated with 4N hydrogen chloride in ethyl acetate (5 ml). After removal of solvent by evaporation, the resulting syrup was partitioned between dichloromethane and aqueous sodium carbonate. The organic layer was
15 separated, dried over magnesium sulfate, and evaporated under reduced pressure. The syrup was purified by column chromatography on silica gel using a mixed solvent of dichloromethane: methanol: triethylamine (4:1:0.01). The main fractions were collected and evaporated under reduced pressure to give methyl (2R)-6-benzhydryl-
20 1-(3-aminopropyl)-4-(2-methoxybenzyl)-2-piperazinecarboxylate (240 mg). This compound (240 mg) was dissolved in a mixture of toluene (10 ml) and acetic acid (0.2 ml) and the whole was stirred under reflux for 3 hours. After removal of solvent by evaporation, the resulting syrup was purified by column chromatography on silica gel
25 using a mixed solvent of dichloromethane and methanol (40:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give (10aR)-4-benzhydryl-2-(2-methoxybenzyl)octahydropyrazino[1,2-a][1,4]diazepin-10(2H)-one (170 mg).

30 NMR (CDCl₃, δ): 1.80-4.02 (15H, m), 3.72 (3H, s), 5.67 (1H, t like), 6.76-6.89 (2H, m), 7.09-7.41 (12H, m)
MASS (APCI): 456 (M+H)⁺ (free)

Example 48

35 To an ice-cooled solution of (10aR)-4-benzhydryl-2-(2-

methoxybenzyl)octahydropyrazino[1,2-a][1,4]diazepin-10(2H)-one (100 mg) in tetrahydrofuran (1 ml) was added lithium aluminium hydride (12.5 mg). The whole was stirred at 50-60°C for 1 hour, at that time an additional lithium aluminium hydride (36 mg) was added to the mixture, and stirred at 50-60°C for 5 hours, finally an additional lithium aluminium hydride (10 mg) added, and stirred at 50-60°C for 5 hours. After cooling with ice, the mixture was treated with 1N sodium hydroxide (5 ml), successively acetyl chloride was added to the whole mixture until the amine spot disappeared on TLC. The reaction mixture was washed with aqueous sodium carbonate, dried over magnesium sulfate, and evaporated under reduced pressure. The syrup was purified by preparative TLC with chloroform: methanol (10:1) to give (10aR)-9-acetyl-4-benzhydryl-2-(2-methoxybenzyl)decahydropyrazino[1,2-a][1,4]diazepine (62 mg).

MASS (APCI): 483 (M+H)⁺

Example 49

A mixture of (10aR)-9-acetyl-4-benzhydryl-2-(2-methoxybenzyl)decahydropyrazino[1,2-a][1,4]diazepine (60mg) and 1N hydrochloric acid in methanol (2 ml) was hydrogenated over 10% palladium-charcoal (50% wet, 20 mg) at room temperature under 2-3 atoms for 4 days. After removal of the catalyst by filtration, the filtrate was evaporated under reduced pressure to give (10aR)-9-acetyl-4-benzhydryldecahydropyrazino[1,2-a][1,4]diazepine dihydrochloride. To a mixture of this compound, 2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzaldehyde (33 mg) and N,N-diisopropylethylamine (63 μ l) in dichloromethane (5 ml) was added sodium triacetoxyborohydride (46 mg). The whole was stirred overnight, and washed with 2N sodium hydroxide. The organic layer was separated, dried over magnesium sulfate and evaporated under reduced pressure. The oil was purified by preparative TLC with hexane: ethyl acetate (2:1). The purified material was treated with 4N hydrogen chloride in ethyl acetate to give (10aR)-9-acetyl-4-benzhydryl-2-[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]decahydropyrazino[1,2-a][1,4]diazepine dihydrochloride (18

mg).

NMR (DMSO- d_6 , δ): 1.74 (3H, s), 3.87 (3H, s), 2.20-5.20 (17H, m),
7.10-7.84 (13H, m), 10.00-10.50 (2H, m)

MASS (APCI): 619 (M+H)⁺(free)

5

Example 50

The following compound was obtained according to a similar manner to that of Preparation 21.

10 (6R, 9aR)-6-Benzhydryl-8-(2-methoxybenzyl)-
octahydropyrazino[2,1-c][1,4]thiazine

IR (KBr): 1597, 1495, 1456, 1240, 1113, 1030 cm^{-1}

NMR (CDCl₃, δ): 1.94-2.80 (10H, m), 3.24-3.52 (4H, m), 3.70
(3H, s), 4.23 (1H, d J=6.9Hz), 6.70-7.32 (14H, m)

15 MASS (APCI): 445 (M+H)⁺

Preparation 35

tert-Butyl (4R, 7S, 8aS)-4-Benzhydryl-7-
hydroxyhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (90 mg) was
20 dissolved in 4N hydrogen chloride in ethyl acetate (5.5 ml) and the
mixture was stirred at room temperature for 1 hour. The volatile
materials were evaporated in vacuo. The residue was partitioned
between ethyl acetate and saturated aqueous sodium bicarbonate and
the organic phase was washed with brine, dried over magnesium
25 sulfate, and evaporated in vacuo to give (4R, 7S, 8aS)-4-
benzhydryloctahydropyrrolo[1,2-a]pyrazin-7-ol (71.3 mg).

NMR (CDCl₃, δ): 1.86-2.69 (10H, m), 3.01-3.26 (2H, m), 4.03-
4.10 (2H, m), 7.13-7.41 (10H, m)

MASS (APCI): 309 (M+H)⁺

30

Preparation 36

The following compounds were obtained according to a similar manner to that of Preparation 35.

35 (1) (4R, 7R, 8aS)-4-Benzhydryloctahydropyrrolo[1,2-a]pyrazin-7-ol

NMR (CDCl₃, δ): 1.61-1.74 (4H, m), 1.95 (1H, dd, J=11.3, 4.0Hz), 2.36-2.54 (3H, m), 2.70-3.52 (4H, m), 3.92 (1H, d, J=9.48Hz), 4.13-4.18 (1H, m), 7.12-7.43 (10H, m)
MASS (API-ES): 309 (M+H)⁺

5

(2) (4R, 7S, 8aS)-4-Benzhydryloctahydropyrrolo[1,2-a]pyrazine-7-carbonitrile

NMR (CDCl₃, δ): 2.04-2.82 (8H, m), 2.94-3.31 (3H, m), 3.99-4.17 (2H, m), 7.11-7.43 (10H, m)

10

MASS (APCI): 318 (M+H)⁺

Preparation 37

The following compounds were obtained according to a similar manner to that of Preparation 1.

15

(1) N-[(4R, 7R, 8aS)-4-Benzhydryloctahydropyrrolo[1,2-a]pyrazin-7-yl]acetamide dihydrochloride

NMR (DMSO-d₆, δ): 1.71 (3H, s), 2.94-4.45 (13H, m), 7.21-7.52 (10H, m), 8.18 (1H, m), 9.72 (2H, m)

20

MASS (APCI): 350 (M+H) (free)

(2) (6R, 9aR)-6-Benzhydryl-2-(3-pyridylcarbonyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride

MASS (APCI): 413 (M+H)⁺ (free)

25

Preparation 38

The following compound was obtained according to a similar manner to that of Preparation 19.

30

4-Benzyl 1-tert-butyl (2S)-2-(hydroxymethyl)-1,4-piperazinedicarboxylate

NMR (CDCl₃, δ): 1.46 (9H, s), 2.52 (1H, br), 2.91-3.00 (3H, m), 3.58 (2H, m), 3.84-4.17 (4H, m), 5.15 (2H, s), 7.35-7.45 (5H, m)

35

Preparation 39

The following compound was obtained according to a similar manner to that of Preparation 20.

5 4-Benzyl-1-tert-butyl (2S)-2-formyl-1,4-piperazinedicarboxylate

MASS (ESI negative): 347 (M-H)

Preparation 40

10 The following compound was obtained according to a similar manner to that of Preparation 21.

4-Benzyl 1-tert-butyl (2R)-2-[[N-(2-methoxybenzyl)-N-(2-oxo-3,3-diphenylpropyl)amino]methyl]-1,4-piperazinedicarboxylate

15 NMR (CDCl₃, δ): 1.41 (9H, s), 2.70-5.52 (19H, m), 6.73-7.29 (19H, m)

MASS (ESI): 678 (M+H)⁺

Preparation 41

20 The following compound was obtained according to a similar manner to that of Preparation 32.

Benzyl (6R,9aR)-6-benzhydryl-8-(2-methoxybenzyl)octahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate

25 NMR (CDCl₃, δ): 1.88 (2H, m), 2.03 (1H, m), 2.49 (2H, m), 2.68 (2H, m), 2.91 (2H, m), 3.28-3.42 (3H, m), 3.67 (3H, s), 3.67-3.78 (2H, m), 4.17 (1H, d, J=5.7Hz), 5.07 (2H, s), 6.76-6.85 (2H, m), 7.11-7.37 (17H, m)

MASS (APCI): 562 (M+H)⁺

30

Preparation 42

The following compound was obtained according to a similar manner to that of Preparation 18.

35 (6R,9aR)-6-Benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-

carboxylate dihydrochloride

$[\alpha]_D^{23.8}$: -60.4411 (C=0.34, MeOH 6.8 mg in 2 ml)

mp: 235-236°C

IR (KBr): 3423, 2588, 2467, 2441, 1703, 1423, 1265, 1230, 1163,
5 1142, 1049 cm^{-1}

NMR ($\text{DMSO}-d_6$ - D_2O , δ): 2.40-3.80 (11H, m), 4.22-4.58 (2H, m),
5.08 (2H, s), 7.14-7.52 (15H, m)

MASS (ES+): 442.3 (M+H)⁺ (free)

10 Preparation 43

To a solution of benzyl (6R,9aR)-6-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate dihydrochloride (10.01 g) and triethylamine (4.13 g) in dichloromethane (50 ml) was added di-tert-butyl dicarbonate (4.46 g) at room temperature and stirred at the
15 same temperature for 1.5 hours. The mixture was poured into water (50 ml) and the pH of the aqueous layer was adjusted to 5 with 1N hydrochloric acid. The organic layer was separated, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by column
20 chromatography on silica gel (120 g) using a mixed solvent of hexane and ethyl acetate (1:3). The fractions containing the objective compound were collected and evaporated under reduced pressure to give 8-benzyl 2-tert-butyl (4R,9aS)-4-benzhydrylhexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate (10.6 g) as colorless
25 syrup.

NMR (CDCl_3 , δ): 1.32 (9H, br), 1.80-4.20 (13H, m), 5.09 (2H, s), 7.10-7.45 (15H, m)

MASS (API-ES): 542 (M+H)⁺

30 Preparation 44

A solution of 8-benzyl 2-tert-butyl (4R,9aS)-4-benzhydrylhexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate (11.0 g) in methanol (110 ml) was hydrogenated over 10% palladium on activated carbon (50% wet, 2.8 g) at room temperature under
35 atmospheric pressure for 4 hours. After removal of the catalyst by

filtration, the filtrate was evaporated under reduced pressure to give tert-butyl (4R,9aS)-4-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (8.0 g) as an oil.

MASS (API-ES): 408 (M+H)⁺

5

Preparation 45

The following compound was obtained according to a similar manner to that of Preparation 31.

10 tert-Butyl (4R,9aS)-4-benzhydryl-8-
[(benzyloxy)acetyl]octahydro-2H-pyrazino[1,2-a]pyrazine-2-
carboxylate

NMR (CDCl₃, δ): 1.33 (9H, br s), 1.90-4.30 (15H, m), 4.54-4.57
(2H, m), 7.17-7.34 (15H, m)

15 MASS (ESI): 556 (M+H)⁺

Preparation 46

To a solution of tert-butyl (4R,9aS)-4-benzhydryl-8-
[(benzyloxy)acetyl]octahydro-2H-pyrazino[1,2-a]pyrazine-2-
20 carboxylate (499.6 mg) in dichloromethane (2.5 ml) was added
trifluoroacetic acid (2.5 ml) at 0°C. Then the mixture was stirred
at room temperature for 1.5 hours and evaporated to dryness. The
residue was added aqueous saturated sodium bicarbonate (20 ml) and
extracted with ethyl acetate (x3). The combined organic extracts
25 were dried over sodium sulfate and evaporated under reduced pressure
to give (6R,9aR)-6-benzhydryl-2-[(benzyloxy)acetyl]octahydro-2H-
pyrazino[1,2-a]pyrazine (467.6 mg) as an oil.

NMR (CDCl₃, δ): 1.93-4.22 (15H, m), 4.54 (2H, s), 7.11-7.34
(15H, m)

30 MASS (APCI⁺): 456 (M+H)⁺

Preparation 47

A mixture of (6R,9aR)-6-benzhydryl-2-[(benzyloxy)acetyl]-
octahydro-2H-pyrazino[1,2-a]pyrazine (450 mg), 20% palladium
35 hydroxide on carbon (120 mg) and concentrated hydrochloric acid

(0.146 ml) in methanol (10 ml) was hydrogenated with 3 atmospheric hydrogen at room temperature for 2 hours. And then to the mixture was added additional 20% palladium hydroxide on carbon (120 mg), and the mixture was hydrogenated under the same condition for 18 hours.

- 5 The mixture was filtered, and the filtrate was evaporated under reduced pressure to give 2-[(6R,9aR)-6-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethanol dihydrochloride (372.8 mg) as a solid.

NMR (DMSO- d_6 , δ): 2.30-5.20 (15H, m), 7.18-7.45 (10H, m)

- 10 MASS (APCI+): 366 (M+H)⁺(free)

Preparation 48

- 2-[(6R,9aR)-6-Benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethanol dihydrochloride (200 mg) was partitioned between
15 aqueous saturated sodium bicarbonate and dichloromethane. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure to give 2-[(6R,9aR)-6-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethanol (170 mg) as an oil.

- 20 MASS (APCI): 366 (M+H)⁺

Preparation 49

- To an ice-cooling mixture of tert-butyl (4R,9aS)-4-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (407
25 mg), triethylamine (0.21 ml) and nicotinic acid (123 mg) in dichloromethane (20 ml) was added 2-chloro-1-methylpyridinium iodide (255 mg), and the whole was stirred at room temperature for 14 hours. The mixture was washed with aqueous sodium bicarbonate and water successively, dried over sodium sulfate and evaporated under reduced
30 pressure. The residue was purified by column chromatography on silica gel using a mixed solvent of dichloromethane and methanol (40:1). The fractions containing the objective compound were collected and concentrated under reduced pressure to give a syrup of tert-butyl (4R,9aS)-4-benzhydryl-8-(3-pyridylcarbonyl)octahydro-2H-
35 pyrazino[1,2-a]pyrazine-2-carboxylate (300 mg).

NMR (CDCl₃, δ): 1.31 (9H, s), 1.50-4.30 (13H, m), 7.10-7.40 (11H, m), 7.70-7.75 (1H, m), 8.61-8.66 (2H, m)

MASS (APCI): 535 (M+Na), 513 (M+H)⁺

5 Preparation 50

The following compound was obtained according to a similar manner to that of Example 42 followed by Preparation 1.

(6R,9aR)-6-Benzhydryl-2-(2-pyridylcarbonyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride

NMR (DMSO-d₆, δ): 2.10-5.20 (13H, m), 7.20-7.70 (12H, m), 7.90-8.00 (1H, m), 8.50-8.55 (1H, m), 9.63 (3H, br s)

MASS (APCI): 413 (M+H)⁺ (free)

15 Preparation 51

To an ice-cooling solution of tert-butyl (4R,9aS)-4-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (0.95 g) and triethylamine (0.49 ml) in dichloromethane (20 ml) was added a solution of dimethylcarbamic chloride (0.26 ml) in dichloromethane (4 ml) dropwisely over 30 minutes and the whole was stirred at the same temperature for 1.5 hours. Additional triethylamine (0.5 ml) and dimethylcarbamic chloride (0.26 ml) were added to the mixture and then the whole was stirred for 2 hours. The mixture was washed with aqueous sodium bicarbonate and water sucessively, dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (1:1). The fractions containing the objective compound were collected and concentrated under reduced pressure to give an oil of (6R,9aR)-6-benzhydryl-8-(tert-butoxycarbonyl)-N,N-dimethyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxamide (1.07 g).

NMR (CDCl₃, δ): 1.32 (9H, s), 1.80-3.80 (12H, m), 2.80 (6H, s), 4.15 (1H, d, J=7.1Hz), 7.12-7.30 (10H, m)

MASS (APCI): 478 (M+H)⁺, 501 (M+Na)

The oil was treated with 4N hydrogen chloride in ethyl acetate (2.5 ml), the resulting precipitate was collected by filtration, washed with diisopropyl ether, and dried in vacuo to give a powder of (6R, 9aR)-6-benzhydryl-N,N-dimethyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxamide dihydrochloride (0.91 g).

NMR (DMSO- d_6 , δ): 2.20-4.50 (19H, m), 2.80 (6H, s), 7.20-7.46 (10H, m), 9.50 (2H, br s)

MASS (APCI): 379 (M+H)⁺, 401 (M+Na) (free)

10 Preparation 52

To an ice-cooling solution of tert-butyl (4R, 9aS)-4-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (1.53 g) and pyridine (0.3 ml) in dichloromethane (40 ml) was added a solution of (1S)-2-chloro-1-methyl-2-oxoethyl acetate (0.522 ml) in 15 dichloromethane (4 ml) dropwisely over 30 minutes, and the whole was stirred at the same temperature for 1.5 hours. Additional (1S)-2-chloro-1-methyl-2-oxoethyl acetate (0.06 ml) and pyridine (0.1 ml) were added to the mixture and the whole was stirred further for 2 hours. The mixture was washed with aqueous sodium bicarbonate and 20 water successively, dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (9:1). The fractions containing the objective compound were collected and concentrated under reduced pressure to give a white 25 powder of tert-butyl (4R, 9aS)-8-[(2S)-2-(acetyloxy)propanoyl]-4-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (1.62 g).

NMR (CDCl₃, δ): 1.22-1.42 (12H, m), 2.20-2.31 (3H, m), 2.30-4.20 (13H, m), 5.26-5.30 (1H, m), 7.15-7.35 (10H, m)

30 MASS (APCI): 544 (M+Na)⁺, 522 (M+H)⁺

Preparation 53

To an ice-cooling solution of tert-butyl (4R, 9aS)-8-[(2S)-2-(acetyloxy)propanoyl]-4-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (1.9 g) in methanol (10 ml) was added 1N 35

sodium hydroxide (5.5 ml), and the mixture was stirred at the same temperature for 1.5 hours. The mixture was concentrated under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was separated and dried over magnesium sulfate, and concentrated under reduced pressure. The residue was treated with 4N hydrogen chloride in ethyl acetate (8 ml), the resulting precipitate was collected by filtration, washed with diisopropyl ether, and dried in vacuo to give a powder of (2S)-1-[(6R,9aR)-6-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-1-oxo-2-propanol dihydrochloride (1.59 g).

NMR (DMSO- d_6 , δ): 1.14 (3H, d, $J=6.2\text{Hz}$), 2.20-4.50 (14H, m),

7.20-7.45 (10H, m), 9.36 (1H, br s)

MASS (APCI): 380 (M+H)⁺ (free)

15 Preparation 54

To an ice-cooling mixture of tert-butyl (4R,9aS)-4-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (0.5 g) in a mixture of tetrahydrofuran (10 ml) and saturated aqueous sodium bicarbonate was added 3-chloro-3-oxopropyl acetate (0.35 ml) in tetrahydrofuran (2 ml) over 10 minutes. After stirring for 30 minutes at the same temperature, the reaction mixture was extracted with ethyl acetate. The extract was dried over magnesium sulfate and evaporated under reduced pressure. The residue was dissolved into methanol (10 ml) and thereto 1N sodium hydroxide (1.2 ml) and the whole was stirred for 1 hour. After removal of the solvent, the residue was partitioned between water and dichloromethane. The organic layer was separated, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixed solvent of dichloromethane and methanol (40:1). The fractions containing the objective compound were collected and concentrated under reduced pressure to give an intermediate of tert-butyl (4R,9aS)-8-(3-acetoxypropanoyl)-4-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate.

35 NMR (CDCl₃, δ): 1.32 (9H, br s), 1.80-4.30 (20H, m), 7.19-7.30

(10H, m)

MASS (API-ES): 524 (M+Na)⁺, 502 (M+H)⁺

The intermediate was treated with 4N hydrogen chloride in dioxane (5 ml), the resulting precipitate was collected by filtration, washed with diisopropyl ether, and dried in vacuo to give powders of 3-[(6R,9aR)-6-benzhydryloctahydro-2H-pyrazino[1,2-
alpyrazin-2-yl]-3-oxo-1-propanol dihydrochloride (0.47 g).

MASS (API-ES): 402 (M+Na)⁺, 380 (M+H)⁺

10

Preparation 55

The following compound was obtained according to a similar manner to that of preparation 29.

15 (R)-2-Benzhydryl-4-benzylpiperazine

mp: 133-135°C

IR (KBr): 1491, 1448, 1138 cm⁻¹

NMR (CDCl₃, δ): 1.86-2.15 (2H, m), 2.57-2.95 (4H, m), 3.28 (1H, d, J=13.0Hz), 3.46-3.68 (1H, m), 3.56 (1H, d, J=13.0Hz),

20

3.83 (1H, d, J=10.5Hz), 7.05-7.45 (15H, m)

MASS (ES⁺): 365 (M+Na)⁺, 343 (M+H)⁺

Preparation 56

To a solution of (R)-2-benzhydryl-4-benzylpiperazine (4.57 g) in a mixture of acetone (25 ml) and tetrahydrofuran (40 ml) was added triethylamine (2.42 ml) and water (30 ml). Di-tert-butyl dicarbonate (3.49 g) was added to the reaction mixture with water bath cooling and the whole was stirred overnight. Sodium chloride and isopropyl ether were added to the mixture and the organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was triturated with hexane to give (R)-2-benzhydryl-4-benzylpiperazine-1-carboxylic acid tert-butyl ester (4.545 g) as a powder. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on (silica gel hexane:ethyl acetate (1:0 to 10:1) as

35

eluent) to give the second crop (0.837g).

mp: 108.5-109°C

IR (KBr): 1687, 1421, 1363, 1172, 1147 cm^{-1}

NMR (CDCl_3 , δ): 1.29 and 1.38 (9H, s), 1.90-2.15 (2H, m),

5 2.55-4.05 (6H, m), 4.70-5.06 (2H, m), 7.02-7.52 (15H, m)

MASS (ES⁺): 466 (M+Na)⁺ 443 (M+H)⁺

Preparation 57

To a solution of (R)-2-benzhydryl-4-benzylpiperazine-1-
10 carboxylic acid tert-butyl ester (5.30 g) in a mixture of
tetrahydrofuran (53 ml) and methanol (53 ml) was added 10% palladium
hydroxide on carbon (0.53 g) and the mixture was hydrogenated with 3
atmospheric hydrogen at 40°C for 20 hours. After cooling, the
mixture was filtered and the filtrate was evaporated in vacuo to
15 give (R)-2-benzhydrylpiperazine-1-carboxylic acid tert-butyl ester
(4.49 g).

mp: 100-105°C

IR (KBr): 16769, 1412, 1169, 1097 cm^{-1}

NMR (CDCl_3 , δ): 1.28 and 1.43 (9H, s), 2.55-4.05 (6H, m),

20 5.70-5.10 (2H, m), 7.05-7.50 (10H, m)

MASS (APCI): 343 (M+H)⁺

MASS (ES⁺): 375 (M+Na)⁺, 353 (M+H)⁺, 297 (M-tBu)⁺

Preparation 58

25 To a solution of 2,6-dimethoxy-3-nitrobenzoic acid (156.15 g)
and methyl iodide (66 ml) in N,N-dimethylformamide (460 ml) was
added potassium carbonate (142 g) portionwise with water bath
cooling. After 3 hours of stirring, the mixture was poured into
ice-water (4.51 ml) and the whole was stirred for 3 hours. The
30 resulting precipitates were collected by filtration, washed with
water, and dried to give methyl 2,6-dimethoxy-3-nitrobenzoate
(164.73 g).

mp: 77-78°C

IR (KBr): 1739, 1593, 1522, 1354, 1300, 1263, 1117, 1086 cm^{-1}

35 NMR (CDCl_3 , δ): 3.90 (3H, s), 3.94 (3H, s), 3.95 (3H, s), 6.76

(1H, d, J=9.3Hz), 8.09 (1H, d, J=9.3Hz)

MASS (ES+): 264 (M+Na)⁺

Preparation 59

5 The following compounds were obtained according to a similar manner to that of Preparation 58.

(1) Methyl 3-chloro-2,6-dimethoxy-5-nitrobenzoate

NMR (CDCl₃, δ): 3.95 (3H, s), 3.98 (6H, s), 8.06 (1H, s)

10 MASS (ESI+): 298 (M+Na)

(2) Methyl 2,4-dichloronicotinate

NMR (CDCl₃, δ): 4.00 (3H, s), 7.33 (1H, d, J=5.38Hz), 8.35 (1H, d, J=5.36Hz)

15

Preparation 60

A solution of 2,6-dimethoxy-3-nitrobenzoic acid methyl ester (5.0 g) in a mixture of methanol (25 ml) and tetrahydrofuran (25 ml) was hydrogenated with 10% palladium on carbon (50% wet, 0.5 g) for 20 days. The mixture was filtered and evaporated in vacuo to give 3-amino-2,6-dimethoxybenzoic acid methyl ester (4.462 g).

mp: 78-80°C

IR (ATR): 3457, 3365, 1712, 1494, 1255, 1081 cm⁻¹

25 NMR (CDCl₃, δ): 3.75 (3H, s), 3.82 (3H, s), 3.93 (3H, s), 6.55 (1H, d, J=8.7Hz), 6.74 (1H, d, J=8.7Hz)

MASS (ES+): 234 (M+Na)⁺, 212 (M+H)⁺

Preparation 61

30 The following compound was obtained according to a similar manner to that of Preparation 60.

Methyl 5-amino-2,4-dimethoxynicotinate

NMR (CDCl₃, δ): 3.48 (1H, br s), 3.87 (3H, s), 3.90 (3H, s), 3.92 (3H, s), 7.66 (1H, s)

35 MASS (API-ES): 213 (M+H)⁺

Preparation 62

To a solution of 3-amino-2,6-dimethoxybenzoic acid methyl ester (4.41 g) and triethylamine (3.8 ml) in methylene chloride (45 ml) was added dropwise a solution of trifluoroacetic anhydride (3.54 ml) in methylene chloride (3.5 ml) with ice salt bath cooling. After stirring for 0.5 hour, water was added to the mixture. The organic layer was separated, washed with brine, dried over magnesium sulfate and silica gel (19.2 g), and evaporated in vacuo to give 2,6-dimethoxy-3-[(trifluoroacetyl)amino]benzoic acid methyl ester (5.20 g).

mp: 112-113°C

IR (KBr): 1739, 1593, 1522, 1354, 1300, 1263, 1117, 1086 cm⁻¹

NMR (CDCl₃, δ): 3.84 (3H, s), 3.88 (3H, s), 3.95 (3H, s), 6.71 (1H, d, J=9.1Hz), 8.26 (1H, d, J=9.1Hz), 8.32 (1H, brs)

MASS (ES⁺): 330 (M+Na)⁺, 308 (M+H)⁺

Preparation 63

The following compounds were obtained according to a similar manner to that of Preparation 62.

(1) Methyl 2,4-dimethoxy-5-[(trifluoroacetyl)amino]nicotinate

NMR (CDCl₃, δ): 3.95 (3H, s), 3.96 (3H, s), 4.01 (3H, s), 8.15 (1H, br s), 8.98 (1H, s)

MASS (API-ES): 309 (M+Na)⁺

(2) Methyl 2,6-diethoxy-3-[(trifluoroacetyl)amino]benzoate

NMR (CDCl₃, δ): 1.41 (3H, t, J=7.0Hz), 3.93 (6H, s), 4.04 (4H, q, J=7.0Hz), 6.69 (1H, d, J=9.18Hz), 8.23 (1H, d, J=9.10Hz), 8.40 (1H, br s)

MASS (API-ES): 358 (M+Na)⁺

(3) Ethyl 6-methoxy-2-methyl-3-[(trifluoroacetyl)amino]benzoate

NMR (CDCl₃, δ): 1.38 (3H, t, J=7.1Hz), 2.16 (3H, s), 3.83 (3H, s), 4.40 (2H, q, J=7.1Hz), 6.81 (1H, d, J=8.9Hz), 7.57

(1H, d, J=8.9Hz)

MASS (ESI+): 306.38 (M+H)⁺

(4) Methyl 3-chloro-2,6-dimethoxy-5-[(trifluoroacetyl)-
amino]benzoate

NMR (CDCl₃, δ): 3.89 (3H, s), 3.89 (3H, s), 4.00 (3H, s), 8.38
(1H, s)

MASS (ESI+): 364 (M+Na)

10 Preparation 64

A solution of 2,6-dimethoxy 3-[(trifluoroacetyl)amino]benzoic acid methyl ester (5.09 g) in carbon tetrachloride (60 ml) was added triphenylphosphine (6.74 g) and the whole was refluxed for 15 hours. After cooling, diisopropyl ether (60 ml) was added and the mixture was stirred for 1 hour with ice bath cooling. The resulting precipitates were removed by filtration and the filtrate was evaporated in vacuo. The residue was dissolved in N,N-dimethylformamide (37 ml) and sodium azide (3.23 g) was added to the solution with water bath cooling. After stirring for 1 hour, the mixture was poured into a mixture of ice water (180 ml) and ethyl acetate (100 ml). The organic layer was separated, dried over magnesium sulfate, and evaporated in vacuo. The residue was triturated with diisopropyl ether (20 ml) and the resulting precipitates were removed by filtration and the filtrate was evaporated in vacuo. The residue was dissolved in methylene chloride and the solution was treated with silica gel to give methyl 2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzoate (5.08 g).

IR (ATR): 1735, 1598, 1494, 1309, 1261, 1163, 1075 cm⁻¹

NMR (CDCl₃, δ): 3.65 (3H, s), 3.94 (3H, s), 3.96 (3H, s), 6.81
(1H, d, J=8.9Hz), 7.38 (1H, d, J=7.9Hz)

MASS (ES+): 355 (M+Na)⁺, 333 (M+H)⁺

Preparation 65

35 The following compounds were obtained according to a similar

manner to that of Preparation 64.

- (1) Methyl 2,4-dimethoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]nicotinate
5 NMR (CDCl₃, δ): 3.85 (3H, s), 3.97 (3H, s), 4.08 (3H, s), 8.13 (1H, s)
MASS (API-ES): 356 (M+Na)⁺
- (2) Methyl 2,6-diethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzoate
10 NMR (CDCl₃, δ): 1.03 (3H, t, J=7.0Hz), 1.44 (3H, t, J=7.0Hz), 3.80 (2H, q, J=7.0Hz), 3.93 (3H, s), 4.15 (2H, q, J=7.0Hz), 6.79 (1H, d, J=8.96Hz), 7.35 (1H, d, J=8.94Hz)
MASS (API-ES): 383 (M+Na)⁺
- (3) Ethyl 6-methoxy-2-methyl-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzoate
15 NMR (CDCl₃, δ): 1.40 (3H, t, J=7.2Hz), 1.92 (3H, s), 3.93 (3H, s), 4.43 (2H, q, J=7.2Hz), 6.95 (1H, d, J=8.9Hz), 7.29 (1H, d, J=8.9Hz)
20
- (4) Methyl 3-chloro-2,6-dimethoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzoate
25 NMR (CDCl₃, δ): 3.64 (3H, s), 3.99 (3H, s), 4.02 (3H, s), 7.51 (1H, s)
MASS (ESI⁺): 389.1 (M+Na)

Preparation 66

A solution of methyl 2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzoate (0.8 g) in toluene (13 ml) was added a
30 solution of diisobutyl aluminum hydride (1.01N in toluene, 6.2 ml) with ice salt bath cooling under nitrogen atmosphere and the mixture was stirred for 20 minutes. The mixture was made acidic by diluted hydrochloric acid and was extracted with ethyl acetate. The extract
35 was washed with brine, dried over magnesium sulfate, and evaporated

in vacuo. The residue was triturated with a mixture of petroleum ether and diisopropyl ether and the resulting precipitate was collected by filtration, and dried to give [2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methanol (586 mg).

5 mp: 74-79°C

IR (KBr): 3477, 1597, 1539, 1498, 1198, 1169, 1088 cm^{-1}

NMR (CDCl_3 , δ): 2.35 (1H, br s), 3.64 (3H, s), 3.99 (3H, s),
4.78 (2H, s), 6.86 (1H, d, $J=8.9\text{Hz}$), 7.32 (1H, d,
 $J=8.9\text{Hz}$)

10 MASS (ES+): 327 (M+Na)⁺, 305 (M+H)⁺

Preparation 67

The following compounds were obtained according to a similar manner to that of Preparation 66.

15

(1) [2,4-Dimethoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]-3-pyridyl]methanol

NMR (CDCl_3 , δ): 3.76 (3H, s), 2.31 (1H, t, $J=6.82\text{Hz}$), 4.10 (3H, s),
4.75 (2H, d, $J=6.78\text{Hz}$), 8.12 (1H, s)

20

MASS (API-ES): 328 (M+Na)⁺

(2) [2,6-Diethoxy-3-[5-(trifluoroethyl)-1H-tetrazol-1-yl]phenyl]methanol

25 NMR (CDCl_3 , δ): 1.80 (3H, t, $J=7.0\text{Hz}$), 1.52 (3H, t, $J=7.0\text{Hz}$),
3.77 (2H, q, $J=7.0\text{Hz}$), 4.20 (2H, q, $J=7.0\text{Hz}$), 4.78 (2H, br s),
6.82 (1H, d, $J=8.92\text{Hz}$), 7.30 (1H, d, $J=8.82\text{Hz}$)

MASS (API-ES): 355 (M+Na)⁺

30

(3) [6-Methoxy-2-methyl-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methanol

NMR (CDCl_3 , δ): 2.01 (3H, s), 3.95 (3H, s), 4.82 (2H, s), 6.93
(1H, d, $J=4.4\text{Hz}$), 7.22 (1H, d, $J=4.4\text{Hz}$)

35

(4) [3-Chloro-2,6-dimethoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methanol

NMR (CDCl₃, δ): 3.62 (3H, s), 4.07 (3H, s), 4.80 (2H, d, J=6.3Hz), 7.45 (1H, s)

Preparation 68

5 To a solution of [2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methanol in methylene chloride (14 ml) was added 4-methylmorpholine N-oxide (755 mg) and molecular sieves 4A (2.8 g), and the mixture was stirred at room temperature for 20 minutes. Tetrapropylammonium perruthenate (97 mg) was added to the
10 mixture and the whole was stirred for 1 hour. The mixture was filtered through cerite and silica gel (45 g) and washed with ethyl acetate. The filtrate and washings were combined, evaporated in vacuo to give crude 2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzaldehyde (1.123 g). It was triturated with
15 diisopropyl ether, collected by filtration, and dried to give pure one (971 mg).

mp: 145-147°C

IR (KBr): 1689, 1599, 1495, 1406, 1184, 1090 cm⁻¹

20 NMR (CDCl₃, δ): 3.71 (3H, s), 4.04 (3H, s), 6.94 (1H, d, J=9.0Hz), 7.55 (1H, d, J=9.0Hz), 10.48 (1H, s)

MASS (ES⁺): 357 (M+Na+MeOH)⁺, 325 (M+Na)⁺, 393 (M+H)⁺

Preparation 69

The following compounds were obtained according to a similar
25 manner to that of Preparation 68.

(1) 2,4-Dimethoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]nicotinaldehyde

30 NMR (CDCl₃, δ): 3.86 (3H, s), 4.16 (3H, s), 8.29 (1H, s), 10.41 (1H, s)

(2) 6-Methoxy-2-methyl-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzaldehyde

35 NMR (CDCl₃, δ): 2.15 (3H, s), 4.04 (3H, s), 7.06 (1H, d, J=8.9Hz), 7.43 (1H, d, J=8.9Hz), 10.65 (1H, s)

(3) 3-Chloro-2,6-dimethoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzaldehyde

NMR (CDCl₃, δ): 3.70 (3H, s), 4.10 (3H, s), 7.69 (1H, s), 10.40 (1H, s)

MASS (ESI⁺): 391.2 (M+Na+MeOH)

Preparation 70

To an ice-cooled solution of [2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methanol (329 mg) in chloroform (5 ml) was added phosphorus tribromide (0.111 ml) in dichloromethane (1 ml) over 5 minutes and the whole was stirred at the same temperature for 15 minutes followed by room temperature for 10 minutes. The mixture was poured into ice-cooled aqueous sodium bicarbonate and the organic layer was separated, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixed solvent of hexane and ethyl acetate (4:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give crystals of 1-[3-(bromomethyl)-2,4-dimethoxyphenyl]-5-(trifluoromethyl)-1H-tetrazole (280 mg).

mp: 89.5-90.0°C

NMR (DMSO-d₆, δ): 3.66 (3H, s), 4.02 (3H, s), 4.62 (2H, s), 6.85 (1H, d, J=8.9Hz), 7.33 (1H, d, J=8.9Hz)

MASS (API-ES): 391 (Na+M+2)⁺, 389 (Na+M)⁺, 341

Preparation 71

To a solution of diisopropylamine (1.21 g) in tetrahydrofuran (9 ml) was added dropwise 1.56 M solution of butyllithium in hexane (7.0 ml) below -65°C and the mixture was stirred at -78°C for 20 minutes. To this solution was added dropwise 2,4-dichloropyridine (1.47 g) in tetrahydrofuran (8 ml) at -78°C and the resulting mixture was stirred at the same temperature for 20 minutes. Dry ice and iodomethane were added successively and the reaction mixture was allowed to warm to room temperature over 1 hour. The reaction was

quenched with water. The aqueous phase was washed with ethyl acetate, acidified to pH 2 with 1N hydrochloric acid, and extracted twice with ethyl acetates. The combined extracts were washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure to give 2,4-dichloronicotinic acid (1.45 g).

NMR (CD_3OD , δ): 7.56 (1H, d, $J=5.46$), 8.37 (1H, d, $J=5.44\text{Hz}$)

Preparation 72

A mixture of methyl 2,4-dichloronicotinate (90 mg) and sodium methoxide (283 mg) in methanol (1 ml) was heated to reflux for 6 hours. The volatile materials were evaporated under reduced pressure and the residue was partitioned between ethyl acetate and 1N hydrochloric acid. The organic phase was washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure to give methyl 2,4-dimethoxynicotinate (76 mg).

NMR (CDCl_3 , δ): 3.87 (3H, s), 3.91 (3H, s), 3.95 (3H, s), 6.04 (1H, d, $J=6.04\text{Hz}$), 8.10 (1H, d, $J=6.00\text{Hz}$)

MASS (APCI): 198 (M+H)⁺

Preparation 73

To a solution of nitronium tetrafluoroborate (343 mg) in sulfolane (1 ml) was added methyl 2,4-dimethoxynicotinate (34 mg) and the mixture was heated at 80°C for 3 hours. After being cooled to room temperature, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with ethyl acetate-hexane (1:4) to give methyl 2,4-dimethoxy-5-nitronicotinate (9.0 mg).

NMR (CDCl_3 , δ): 3.95 (3H, s), 4.10 (3H, s), 4.04 (3H, s), 8.80 (1H, s)

MASS (API-ES): 243 (M+H)⁺

Preparation 74

To a solution of methyl 2,6-diethoxybenzoate (224 mg) in dichloromethane (2 ml) was added sulfuric acid (216 mg) at -20°C

followed by dropwise addition of nitric acid (69.2 mg) at the same temperature. The reaction mixture was allowed to warm to 0°C over 1 hour. Water was carefully added and the mixture was extracted twice with ethyl acetates. The combined extracts were washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with ethyl acetate-hexane (1:8) to give methyl 2,6-diethoxy-3-nitrobenzoate (113 mg).

NMR (CDCl₃, δ): 1.33-1.50 (6H, m), 3.93 (3H, s), 3.99-4.20 (4H, m), 6.71 (1H, d, J=9.34Hz), 8.05 (1H, d, J=9.36Hz)
MASS (API-ES): 292 (M+Na)⁺

Preparation 75

A solution of methyl 2,6-diethoxy-3-nitrobenzoate (1.56 g) in ethyl acetate (16 ml) was hydrogenated over platinum oxide (78.9 mg) at room temperature for 3 hours. After the catalyst was removed by filtration, the filtrate was concentrated under reduced pressure to give methyl 3-amino-2,6-diethoxybenzoate (1.34 g).

NMR (CDCl₃, δ): 1.22-1.38 (6H, m), 3.91 (3H, s), 3.94-4.13 (4H, m), 6.53 (1H, d, J=8.70Hz), 6.72 (1H, d, J=8.76Hz)
MASS (API-ES): 240 (M+H)⁺

Preparation 76

To a solution of [2,6-diethoxy-3-[5-(trifluoroethyl)-1H-tetrazol-1-yl]phenyl]methanol (88.8 mg) in dimethyl sulfoxide (1 ml) was added a mixture of sulfur trioxide pyridine complex (170 mg) and triethylamine (216 mg) in dimethyl sulfoxide (1 ml), and the mixture was stirred at room temperature for 0.5 hour. The reaction mixture was quenched with saturated aqueous sodium bicarbonate and extracted three times with ethyl acetates. The combined extracts were washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure to give 2,6-diethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzaldehyde (88.3 mg).

NMR (CDCl₃, δ): 1.06 (3H, t, J=7.0Hz), 1.54 (3H, t, J=7.0Hz), 3.90 (2H, q, J=7.0Hz), 4.25 (2H, q, J=7.0Hz), 6.90 (1H,

d, $J=9.02\text{Hz}$), 7.53 (1H, d, $J=8.98\text{Hz}$), 10.49 (1H, s)

MASS (API-ES): 353 (M+Na)⁺

Preparation 77

5 To a solution of ethyl 2-methoxy-6-methylbenzoate (250 mg) in carbon tetrachloride (10 ml) was added dropwise bromine (66.3 μl) at room temperature. After stirring at room temperature overnight, the mixture was poured into a mixture of water and ethyl acetate and separated. The organic layer was separated and the aqueous layer
10 was extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure to give ethyl 3-bromo-6-methoxy-2-methylbenzoate (343.5 mg) as an oil.

NMR (CDCl_3 , δ): 1.36 (3H, t, $J=7.1\text{Hz}$), 2.32 (3H, s), 3.80 (3H,
15 s), 4.40 (2H, q, $J=7.1\text{Hz}$), 6.66 (1H, d, $J=8.9\text{Hz}$), 7.50 (1H, d, $J=8.9\text{Hz}$)

MASS (ESI⁺): 295 and 297 (M+Na)⁺

Preparation 78

20 A mixture of ethyl 3-bromo-6-methoxy-2-methylbenzoate (2.1 g), benzophenone imine (1.55 ml), sodium tert-butoxide (1.03 g), tris(dibenzylideneacetone)dipalladium (1.76 g), and (RS)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (3.59 g) in toluene (20 ml) was stirred under nitrogen atmosphere at 90°C overnight. The
25 mixture was quenched with water and the whole was extracted with ethyl acetate (x3). The combined organic layers were washed with brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified by column chromatography (silica gel (250 ml), ethyl acetate/hexane (1/9)) to give 2.15 g of a yellow
30 oil. To the solution of the oil in tetrahydrofuran (35 ml) was added 1N hydrochloric acid (30 ml) at room temperature, and the mixture was stirred at room temperature for 1 hour. The mixture was quenched with a mixture of aqueous saturated sodium bicarbonate and brine, and the whole was extracted with ethyl acetate (x3). The
35 combined organic layers were washed with brine, dried over magnesium

sulfate, evaporated under reduced pressure. The residue was purified by column chromatography (silica gel (150 ml), ethyl acetate/hexane (1:1)) to give ethyl 3-amino-6-methoxy-2-methylbenzoate (884 mg) as an oil.

5 NMR (CDCl₃, δ): 1.38 (3H, t, J=7.2Hz), 2.06 (3H, s), 3.75 (3H, s), 4.40 (2H, q, J=7.2Hz), 6.67 (1H, d, J=8.8Hz), 6.69 (1H, d, J=8.8Hz)
MASS (ESI⁺): 210.18 (M+H)⁺, 251.2 (M+H+MeCN)⁺

10 Preparation 79

Methyl 3-chloro-2,6-dimethoxy-5-nitrobenzoate (5.0 g) was added to a mixture of iron powder (5.37 g) and ammonium chloride (0.61 g) in ethanol and water, and the mixture was stirred under reflux for 1 hour. After cooling, the mixture was filtered and
15 evaporated. The residue was dissolved in ethyl acetate, washed with water and brine, dried over magnesium sulfate, and evaporated to give methyl 3-amino-5-chloro-2,6-dimethoxybenzoate (3.97 g) as an oil.

20 NMR (CDCl₃, δ): 3.79 (3H, s), 3.81 (3H, s), 3.94 (3H, s), 6.79 (1H, s)
MASS (ESI⁺): 268 (M+Na)⁺

Example 51

The following compounds were obtained according to a similar
25 manner to that of Preparation 34.

(1) (4R,9aR)-8-Acetyl-4-benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

30 NMR (DMSO-d₆, δ): 1.91-1.96 (3H, m), 2.10-4.50 (21H, m), 7.10-7.85 (12H, m)
MASS (APCI): 636 (M+H)⁺ (free)

(2) 3-[(6R,9aR)-6-Benzhydryl-8-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-

35

pyrazino[1,2-a]pyrazin-2-yl]-3-oxo-1-propanol dihydrochloride
NMR (DMSO-d₆, δ): 3.77 (3H, s), 2.20-4.60 (23H, m), 7.05-7.45
(11H, m), 7.84 (1H, d, J=9.0Hz)
MASS (API-ES): 666 (M+H)⁺ (free)

5

Example 52

The following compound was obtained according to a similar manner to that of Preparation 27.

10 (1) (4R,9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(3-pyridylcarbonyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride
NMR (DMSO-d₆, δ): 2.10-5.00 (21H, m), 7.00-8.15 (16H, m), 8.55
(1H, d, J=2.8Hz)
15 MASS (APCI): 699 (M+H)⁺ (free)

(2) (4R,9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(2-pyridylcarbonyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride
20 NMR (DMSO-d₆, δ): 2.10-5.00 (21H, m), 7.00-8.15 (16H, m),
8.50-8.55 (1H, m), 9.00-10.50 (3H, m)
MASS (APCI): 721 (M+Na), 699 (M+H)⁺ (free)

(3) (2S)-1-[(6R,9aR)-6-Benzhydryl-8-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-1-oxo-2-propanol dihydrochloride
25 NMR (DMSO-d₆, δ): 1.13 (3H, d, J=5.6Hz), 1.90-4.52 (22H, m),
7.08-7.86 (12H, m)
MASS (APCI⁺): 666.13 (M+H)⁺

30

(4) 2-[(6R,9aR)-6-Benzhydryl-8-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethanol dihydrochloride
mp: 128-132°C
35 IR (KBr): 3402, 1653, 1599, 1496, 1448, 1238, 1169, 1101 cm⁻¹

NMR (DMSO- d_6 , δ): 3.31 (2H, s), 3.78 (3H, s), 4.05 (3H, s),
2.20-4.80 (16H, m), 7.05-7.50 (11H, m), 7.84 (1H, d,
J=9.0Hz)

MASS (API-ES): 652 (M+H)⁺ (free)

5

- (5) (6R, 9aR)-6-Benzhydryl-8-[2,6-dimethoxy-3-[5-(trifluoromethyl)-
1H-tetrazol-1-yl]benzyl]-N,N-dimethyloctahydro-2H-
pyrazino[1,2-a]pyrazine-2-carboxamide dihydrochloride

10

NMR (DMSO- d_6 , δ): 2.30-4.60 (27H, m), 7.07-7.44 (11H, m), 7.84
(1H, d, J=9.0Hz)

MASS (APCI+): 665.13 (M+H)⁺

15

- (6) 2-[(6R, 9aR)-6-Benzhydryl-8-[[2,4-dimethoxy-5-[5-
(trifluoromethyl)-1H-tetrazol-1-yl]-3-pyridyl]methyl]-
octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethanol
dihydrochloride

20

NMR (CDCl₃, δ) (free form): 1.81-1.98 (1H, m), 1.99-2.18 (2H,
m), 2.30-2.48 (2H, m), 2.52-2.77 (2H, m), 2.82-3.05 (2H,
m), 3.05-3.26 (2H, m), 3.40-3.52 (3H, m), 3.55 (3H, s),
3.82 and 3.86 (total 3H, each s), 3.96-4.26 (4H, m),
7.16-7.30 (10H, m), 8.04 and 8.06 (total 1H, each s)

MASS (API-ES): 653 (M+H)⁺ (free)

25

- (7) 2-[(6R, 9aR)-6-Benzhydryl-8-[2,6-diethoxy-3-[5-trifluoroethyl]-
1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-
yl]-2-oxoethanol dihydrochloride

NMR (CDCl₃, δ) (free form): 0.94 (3H, t, J=7.0Hz), 1.35 (3H, t,
J=7.0Hz), 1.75-3.20 (11H, m), 3.49-4.20 (11H, m), 6.63-
6.70 (1H, m), 7.11-7.29 (11H, m)

30

MASS (API-ES): 680 (M+H)⁺

- (8) 2-[(6R, 9aR)-6-Benzhydryl-8-[6-methoxy-2-methyl-3-[5-
(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-
pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethanol dihydrochloride

35

NMR (DMSO- d_6 , δ): 1.91-1.99 (3H, m), 2.20-4.40 (20H, m), 7.09-

7.41 (11H, m), 7.75 (1H, d, J=8.9Hz)

MASS (APCI⁺): 636.8 (M+H)⁺ (free)

(9) 2-[(6R, 9aR)-6-Benzhydryl-8-[3-chloro-2,6-dimethoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethanol dihydrochloride

NMR (DMSO-d₆, δ): 2.20-4.70 (23H, m), 7.18-7.46 (10H, m), 8.09 (1H, d, J=3.4Hz)

MASS (ESI⁺): 686.3 (M+H)⁺, 708.3 (M+Na) (free)

(10) (4R, 8aS)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazine dihydrochloride

NMR (CDCl₃, δ) (free form): 1.22-1.82 (3H, m), 1.88-2.04 (2H, m), 2.18-2.39 (1H, m), 2.47 (1H, br d, J=10.7Hz), 2.56-2.68 (1H, m), 2.92 (1H, br d, J=10.3Hz), 3.23 (1H, br t, J=8.94Hz), 3.50 (3H, s), 3.59 (3H, s), 3.45-3.69 (3H, m), 3.98-4.00 (2H, m), 6.64 (1H, d, J=8.96Hz), 6.87-7.41 (11H, m)

MASS (APCI): 579 (M+H)⁺

(11) (4R, 7S, 8aS)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo[1,2-a]pyrazin-7-ol dihydrochloride

Free

NMR (CDCl₃, δ): 1.72-2.35 (7H, m), 2.46-2.59 (2H, m), 2.90 (1H, d, J=10.7Hz), 3.19 (1H, d, J=8.64Hz), 3.50 (3H, s), 3.58 (2H, s), 3.62 (3H, s), 3.94-4.10 (2H, m), 6.67 (1H, d, J=8.92Hz), 7.11-7.38 (11H, m)

MASS (APCI): 595 (M+H)⁺

Dihydrochloride

MASS (APCI): 595 (M+H)⁺

- (12) (4R, 7R, 8aS)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo-[1,2-a]pyrazin-7-ol dihydrochloride

NMR (CDCl₃, δ) (free form): 1.41-1.70 (3H, m), 1.80-1.97 (3H, m), 2.43 (1H, br d, J=11.9Hz), 2.72-2.90 (3H, m), 2.98 (1H, dd, J=9.94, 6.0Hz), 3.40-3.57 (3H, m), 3.50 (3H, m), 3.63 (3H, m), 3.88 (1H, d, J=9.82Hz), 4.15 (1H, br s), 6.66 (1H, d, J=8.94Hz), 7.08-7.40 (11H, m)

MASS (APCI): 595 (M+H)⁺ (free)

- (13) (4R, 7S, 8aS)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo-[1,2-a]pyrazine-7-carbonitrile dihydrochloride

NMR (CDCl₃, δ) (free form): 1.69-2.24 (5H, m), 2.39-2.48 (2H, m), 2.62-2.91 (3H, m), 3.21-3.38 (1H, m), 3.49 (3H, s), 3.56 (2H, s), 3.69 (3H, m), 3.95 (1H, d, J=9.96Hz), 6.68 (1H, d, J=8.94Hz), 7.09-7.40 (11H, m)

MASS (API-ES): 604 (M+H)⁺ (free)

- (14) N-[(4R, 7R, 8aS)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydropyrrolo-[1,2-a]pyrazin-7-yl]acetamide dihydrochloride

NMR (DMSO-d₆, δ): 1.70 (3H, s), 1.80-4.80 (20H, m), 7.05 (1H, d, J=9.1Hz), 7.08-7.53 (10H, m), 7.81 (1H, d, J=9.1Hz)

MASS (APCI⁺): 636.07 (M+H)⁺

- (15) Benzyl (6R, 9aR)-6-benzhydryl-8-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate

IR (KBr): 3431, 3402, 1705, 1697, 1498, 1456, 1165, 1099 cm⁻¹

NMR (CDCl₃, δ): 1.70-2.14 (3H, m), 2.22-4.24 (12H, m), 3.50 (3H, s), 3.66 (3H, s), 5.08 (2H, s), 6.67 (1H, d, J=8.9Hz), 7.05-7.44 (16H, m)

MASS (ES⁺): 750 (M+Na)⁺, 728 (M+H)⁺

Example 53

The following compound was obtained according to a similar manner to that of Preparation 33.

5 (4R, 9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(methylsulfonyl)octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

NMR (DMSO-d₆, δ): 2.30-4.50 (24H, m), 7.12-7.38 (11H, m), 7.86 (1H, d, J=9.0Hz)

10 MASS (ESI+): 672 (M+H) (free)

Example 54

The following compounds were obtained according to a similar manner to that of Example 17.

15

(1) (4R, 9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(3-methoxypropanoyl)octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

20 NMR (DMSO-d₆, δ): 2.20-4.50 (20H, m), 3.19 (3H, s), 3.32 (3H, s), 3.51 (2H, t, J=6.5Hz), 7.08-7.41 (11H, m), 7.84 (1H, d, J=9.0Hz)

MASS (ESI+): 680 (M+H), 702 (M+Na) (free)

25

(2) (4R, 9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(methoxyacetyl)octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

NMR (DMSO-d₆, δ): 2.20-4.50 (26H, m), 7.12-7.87 (12H, m)

MASS (ESI+): 666.07 (M+H)⁺ (free)

30

(3) (4R, 9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(ethoxyacetyl)octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

NMR (DMSO-d₆, δ): 1.09 (3H, t, J=6.4Hz), 2.30-4.50 (25H, m), 7.08-7.41 (11H, m), 7.85 (1H, d, J=9.0Hz)

35

MASS (ESI+): 680 (M+H)⁺ (free)

- (4) (4R, 9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(2-pyrazinylcarbonyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride
5 NMR (DMSO-d₆, δ): 2.20-4.50 (21H, m), 7.10-7.38 (11H, m), 7.85 (1H, d, J=8.6Hz), 8.63-8.85 (3H, m)
MASS (ESI+): 700 (M+H), 722 (M+Na) (free)
- (5) (4R, 9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(5-pyrimidinylcarbonyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride
10 NMR (DMSO-d₆, δ): 2.20-4.50 (21H, m), 7.09-7.40 (11H, m), 7.85 (1H, d, J=9.2Hz), 8.86 (2H, s), 9.27 (1H, s)
MASS (ESI+): 700 (M+H), 722 (M+Na) (free)
- (6) (4R, 9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(2-pyrimidinylcarbonyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride
15 NMR (DMSO-d₆, δ): 2.10-4.30 (21H, m), 7.11-7.45 (11H, m), 7.57-7.61 (1H, m), 7.83-7.89 (1H, m), 8.86 (2H, d, J=4.9Hz)
20 MASS (ESI+): 700 (M+H), 722 (M+Na) (free)
- (7) (4R, 9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-[(1-methyl-1H-imidazol-2-yl)carbonyl]octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride
25 NMR (DMSO-d₆, δ): 2.30-4.50 (24H, m), 7.08-7.64 (13H, m), 7.84 (1H, d, J=9.1Hz)
30 MASS (ESI+): 702 (M+H)⁺, 724 (M+Na) (free)
- (8) (4R, 9aR)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-(4-pyrimidinylcarbonyl)octahydro-2H-pyrazino[1,2-a]pyrazine trihydrochloride
35 NMR (DMSO-d₆, δ): 2.20-4.40 (21H, m), 7.11-7.41 (11H, m),

7.62-7.69 (1H, m), 7.86 (1H, d, J=9.2Hz), 8.97 (1H, d, J=5.0Hz), 9.39 (1H, s)

MASS (ESI+): 700 (M+H), 722 (M+Na) (free)

5 Example 55

The following compound was obtained according to a similar manner to that of Preparation 31.

(4R, 9aR)-4-Benzhydryl-8-(cyclobutylcarbonyl)-2-[2,6-dimethoxy-
10 3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine dihydrochloride

NMR (DMSO-d₆, δ): 1.60-4.50 (28H, m), 7.09-7.40 (11H, m), 7.85 (1H, d, J=9.0Hz)

MASS (ESI+): 676 (M+H) (free)

15

Example 56

The following compound was obtained according to a similar manner to that of Example 32.

1-[(6R, 9aR)-6-Benzhydryl-8-[2,6-dimethoxy-3-[5-
20 (trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]acetone trihydrochloride

NMR (DMSO-d₆, δ): 2.15 (3H, s), 2.30-4.60 (23H, m), 7.11-7.31 (11H, m), 7.88 (1H, d, J=9.0Hz)

25 MASS (ESI+): 650 (M+H) (free)

Example 57

The following compounds were obtained according to a similar manner to that of Preparation 28.

30

(1) (2R)-2-Benzhydryl-4-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-1-[(1-methyl-1H-pyrazol-4-yl)methyl]piperazine dihydrochloride

NMR (DMSO-d₆, δ): 2.20-5.30 (21H, m), 6.80-7.80 (14H, m)

35

MASS (APCI): 633 (M+H)⁺(free)

(2) (2R)-2-Benzhydryl-4-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-1-(3-pyridylmethyl)piperazine trihydrochloride

5 NMR (DMSO- d_6 , δ): 2.20-5.00 (18H, m), 7.10-8.60 (16H, m)
MASS (APCI): 630 (M+H)⁺(free)

Example 58

The following compound was obtained according to a similar
10 manner to that of Preparation 8.

(4R,8aS)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]hexahydropyrrolo[1,2-a]pyrazin-7(6H)-on dihydrochloride

15

Free form

NMR (CDCl₃, δ): 1.92-2.59 (6H, m), 2.87-3.05 (3H, m), 3.50 (3H, s), 3.59 (2H, s), 3.66 (3H, s), 3.87 (1H, d, J=9.52Hz), 6.70 (1H, d, J=8.92Hz), 7.15-7.38 (11H, m)

20 MASS (APCI): 593 (M+H)⁺

Dihydrochloride

MASS (APCI): 593 (M+H)⁺

25 Example 59

A solution of benzyl (6R,9aR)-6-benzhydryl-8-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (2.26 g) and triethylamine (0.87 ml) in tetrahydrofuran (34 ml) was hydrogenated over 10%
30 palladium on carbon (50% wet, 0.52 g) under atmospheric pressure at room temperature for 2 hours. The mixture was filtrated and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel with chloroform:methanol:ammonia (20:1:0.1) as eluent to give (4R,9aR)-4-benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-

35

pyrazino[1,2-a]pyrazine (1.738 g).

IR (KBr): 3438, 1597, 1533, 1496, 1198, 1167, 1097 cm^{-1}

NMR (CDCl_3 , δ): 1.66-3.60 (14H, m), 3.50 (3H, s), 3.64 (3H, s),
4.19 (1H, d, $J=7.1\text{Hz}$), 6.66 (1H, d, $J=8.9\text{Hz}$), 7.05-7.35
(11H, m)

MASS (APCI): 594 (M+H)⁺

Example 60

(4R, 9aS)-4-Benzhydryl-2-[2,6-dimethoxy-3-[5-(trifluoromethyl)-
1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino[1,2-a]pyrazine (31.1
mg) was dissolved in ethyl acetate (1 ml), then to the solution was
added 4N hydrogen chloride in ethyl acetate (0.5 ml). The solution
was evaporated and dried under reduced pressure at 50°C for 5 hours
to give (4R, 9aS)-4-benzhydryl-2-[2,6-dimethoxy-3-[5-
(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-pyrazino-
[1,2-a]pyrazine trihydrochloride (32.5 mg) as a solid.

NMR ($\text{DMSO}-d_6$, δ): 2.20-4.50 (21H, m), 7.12-7.32 (11H, m), 7.88
(1H, d, $J=9.0\text{Hz}$)

MASS (ESI⁺): 594 (M+H)⁺(free)

Example 61

The following compound was obtained according to a similar
manner to that of Preparation 27 followed by Preparation 1.


(3R)-3-Benzhydryl-1-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-
tetrazol-1-yl]benzyl]piperazine dihydrochloride

NMR ($\text{DMSO}-d_6$, δ): 2.20-4.80 (10H, m), 3.37 (3H, s), 3.73 (3H,
s), 7.07 (1H, d, $J=9.0\text{Hz}$), 7.78 (1H, d, $J=9.0\text{Hz}$), 7.20-
7.52 (10H, m), 7.75-7.80 (1H, m), 9.75-10.10 (1H, m)


MASS (APCI): 539 (M+H)⁺

C L A I M S

1. A compound of the formula (I):



wherein



in which

R^4 is hydrogen, lower alkanoyl or lower alkyl optionally substituted with carboxy, lower alkoxycarbonyl, pyridyl or lower alkylpyrazolyl,

R^5 is hydrogen or lower alkoxycarbonyl,

R^6 is hydrogen, halogen, oxo, hydroxy, lower alkanoyloxy,

cyano, carbamoyl or amino optionally substituted with lower alkanoyl, hydroxy(lower)alkanoyl or benzyloxycarbonyl,

R⁷ is hydrogen or halogen,

5 R⁸ is hydrogen, oxo, lower alkanoyloxy, azido or amino optionally substituted with lower alkanoyl,

R⁹ is hydrogen; lower alkanoyl optionally substituted with hydroxy, carboxy, lower alkoxy, phenyl(lower)alkoxy, lower alkanoyloxy, lower alkoxycarbonyl, amino, lower alkanoylamino, benzyloxy(lower)alkanoylamino, hydroxy(lower)alkanoylamino, di(lower)alkylcarbamoyl or ~~mono~~(or ~~di~~ or ~~tri~~)halogen(s); cyclo(lower)alkylcarbonyl optionally substituted with hydroxy(lower)alkyl, amino or lower alkanoylamino; azetidinyllcarbonyl; lower 10 alkylimidazolylcarbonyl; pyridylcarbonyl; pyrimidinylcarbonyl; pyrazinylcarbonyl; lower alkyl optionally substituted with imino, cyclo(lower)alkyl, lower alkanoyl, lower alkoxycarbonyl, carbamoyl or di(lower)alkylcarbamoyl; cyclo(lower)alkyl; carbamoyl optionally substituted with ~~mono~~(or di) (lower)alkyl(s); 20 aminosulfonyl optionally substituted with ~~mono~~(or di) (lower)alkyl(s); lower alkylsulfonyl optionally substituted with hydroxy, lower alkylsulfonyl or lower alkanoyloxy; or pyridyl,


25 R¹⁰ is hydrogen or lower alkanoyl,

R¹¹ is hydrogen or oxo, and

R¹, R² and R³ are independently hydrogen, halogen, lower alkyl, lower alkoxy or tetrazolyl optionally substituted with mono(or di or tri)halo(lower)alkyl,

30 and a salt thereof.

2. The compound of claim 1, in which



in which

R^4 is lower alkanoyl or lower alkyl optionally substituted with carboxy, lower alkoxycarbonyl, pyridyl or lower alkylpyrazolyl,

R^5 is hydrogen,

R^6 is halogen, oxo, hydroxy, lower alkanoyloxy, cyano, carbamoyl or amino optionally substituted with lower alkanoyl, hydroxy(lower)alkanoyl or benzyloxycarbonyl,


R^7 is hydrogen,

R^8 is hydrogen,

R^9 is lower alkanoyl substituted with hydroxy, carboxy, lower alkoxy, phenyl(lower)alkoxy, lower alkanoyloxy, lower alkoxycarbonyl, amino, lower alkanoylamino, benzyloxy(lower)alkanoylamino, hydroxy(lower)alkanoylamino, di(lower)alkylcarbamoyl or mono(or di or tri)halogen(s); cyclo(lower)alkylcarbonyl optionally substituted with hydroxy(lower)alkyl, amino or lower alkanoylamino; azetidiny carbonyl; lower alkylimidazolylcarbonyl; pyridylcarbonyl;

- pyrimidinylcarbonyl; pyrazinylcarbonyl; lower alkyl optionally substituted with imino, cyclo(lower)alkyl, lower alkanoyl, lower alkoxy carbonyl, carbamoyl or di(lower)alkylcarbamoyl; cyclo(lower)alkyl; carbamoyl optionally substituted with mono(or di) (lower)alkyl(s); aminosulfonyl optionally substituted with mono(or di) (lower)alkyl(s); lower alkylsulfonyl optionally substituted with hydroxy, lower alkylsulfonyl or lower alkanoyloxy; or pyridyl,
- R^{10} is hydrogen or lower alkanoyl,
 R^{11} is hydrogen or oxo, and
 R^1 , R^2 and R^3 are independently hydrogen, halogen, lower alkyl, lower alkoxy or tetrazolyl optionally substituted with mono(or di or tri)halo(lower)alkyl.

3. The compound of claim 2, in which



- in which
 R^4 is lower alkanoyl or lower alkyl optionally substituted with carboxy, lower alkoxy carbonyl, pyridyl or lower alkylpyrazolyl,
 R^5 is hydrogen,
 R^6 is halogen, oxo, hydroxy, lower alkanoyloxy, cyano, carbamoyl or amino optionally substituted with lower alkanoyl, hydroxy(lower)alkanoyl or benzyloxycarbonyl,
 R^7 is hydrogen,
 R^8 is hydrogen,
 R^9 is lower alkanoyl substituted with hydroxy, carboxy, lower

alkoxy, phenyl(lower)alkoxy, lower alkanoyloxy, lower
alkoxycarbonyl, amino, lower alkanoylamino,
benzyloxy(lower)alkanoylamino,
hydroxy(lower)alkanoylamino, di(lower)alkylcarbamoyl or
5 mono(or di or tri)halogen(s); cyclo(lower)alkylcarbonyl
optionally substituted with hydroxy(lower)alkyl, amino
or lower alkanoylamino; azetidiny carbonyl; lower
alkylimidazolylcarbonyl; pyridylcarbonyl;
pyrimidinylcarbonyl; pyrazinylcarbonyl; lower alkyl
10 optionally substituted with imino, cyclo(lower)alkyl,
lower alkanoyl, lower alkoxycarbonyl, carbamoyl or
di(lower)alkylcarbamoyl; cyclo(lower)alkyl; carbamoyl
optionally substituted with mono(or di) (lower)alkyl(s);
aminosulfonyl optionally substituted with mono(or
15 di) (lower)alkyl(s); lower alkylsulfonyl optionally
substituted with hydroxy, lower alkylsulfonyl or lower
alkanoyloxy; or pyridyl, and
R¹, R² and R³ are independently hydrogen, lower alkoxy or tetrazolyl
substituted with mono(or di or tri)halo(lower)alkyl.

20


4. A compound of claim 3, which is selected from a group
consisting of

- (1) (4R,9aR)-4-benzhydryl-2-[2,6-dimethoxy-3-[5-
(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-8-
25 (methoxyacetyl)octahydro-2H-pyrazino[1,2-a]pyrazine
dihydrochloride,
(2) 2-[(6R,9aR)-6-benzhydryl-8-[2,6-dimethoxy-3-[5-
(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]octahydro-2H-
pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethanol,
30 (3) (6R,9aR)-6-benzhydryl-8-[2,6-dimethoxy-3-[5-
(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-N,N-
dimethyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-
carboxamide,
(4) N-[(4R,7R,8aS)-4-benzhydryl-2-[2,6-dimethoxy-3-[5-
35 (trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-


octahydropyrrolo[1,2-a]pyrazin-7-yl]acetamide, and
 (5) (2R)-2-benzhydryl-4-[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]-1-[(1-methyl-1H-pyrazol-4-yl)methyl]piperazine,
 or a pharmaceutically acceptable salt thereof.


5. A process for the preparation of the compound of claim 1, or a salt thereof, which comprises,


(1) reacting a compound of the formula (II):



(II)





wherein  is as defined in claim 1, or its reactive derivative at the imino group or a salt thereof, with a compound of the formula (III):




(III)

wherein R^1 , R^2 and R^3 are each as defined in claim 1, and W_1 is a leaving group, or a salt thereof to give a compound of the formula (I):



15 (2) reacting a compound of the formula (Ia):



25 wherein R^1 , R^2 and R^3 are each as defined in claim 1, or a salt thereof, with a compound of the formula (IV):




wherein R^9 is as defined in claim 1, and

W_2 is a leaving group,

or a salt thereof to give a compound of the formula (Ib):

35

5




10

wherein R^1 , R^2 , R^3 and R^9 are each as defined in claim 1,
or a salt thereof, or

(3) cyclizing a compound of the formula (V):


15

20



25




wherein R^1 , R^2 and R^3 are each as defined in claim 1,
and
Y is



or its reactive derivative at the imino group or a salt
thereof, to give a compound of the formula (Ic):

30


108



30 wherein R^1 , R^2 , R^3 , R^6 , R^7 , R^8 , R^9 , R^{10} and R^{11} are each
as defined in claim 1,
or a salt thereof, or

(4) reacting a compound of the formula (VI):


35



10 wherein R^1 , R^2 and R^3 are each as defined in claim 1,
or its reactive derivative at the imino group or a salt
thereof with a compound of the formula (VII):



wherein R^{9a} is as defined in claim 1,
to give a compound of the formula (Id):



30 wherein R^1 , R^2 , R^3 and R^{9a} are each as defined in claim 1,
or a salt thereof.

- 35 6. A pharmaceutical composition which comprises, as an active
ingredient, a compound of claim 1 or a pharmaceutically
acceptable salt thereof in admixture with pharmaceutically
acceptable carriers.

7. A compound of claim 1 for use as a medicament.

5 8. A method for treating or preventing Tachykinin-mediated diseases which comprises administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to human being or animals.

10 9. A compound of claim 1 for use as Tachykinin antagonist.

10. Use of a compound of claim 1 for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases.

15

20

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 01/11240

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D403/10 C07D487/04 C07D513/04 A61K31/495 A61P11/00
 A61P27/02 A61P17/00 //(C07D487/04, 209:00, 241:00),
 (C07D487/04, 241:00, 241:00), (C07D513/04, 241:00, 279:00),

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 02 00631 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 3 January 2002 (2002-01-03) claims 1-10	1-10
Y	WO 00 51984 A (MERCK SHARP & DOHME LTD.) 8 September 2000 (2000-09-08) claims 1-15	1-10
A	WO 96 32386 A (BOEHRINGER INGELHEIM) 17 October 1996 (1996-10-17) claims 1-21	1-10
Y	WO 96 34864 A (SCHERING CORPORATION) 7 November 1996 (1996-11-07) claims 1-23	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

24 April 2002

Date of mailing of the international search report

07/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 01/11240

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 (C07D487/04, 241:00, 245:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

24 April 2002

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/JP 01/11240

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0200631	A	03-01-2002	WO 0200631 A2	03-01-2002
WO 0051984	A	08-09-2000	AU 2683300 A WO 0051984 A1	21-09-2000 08-09-2000
WO 9632386	A	17-10-1996	DE 19519245 A1 AU 706209 B2 AU 5687496 A BG 62138 B1 BG 101947 A BR 9604821 A CA 2218096 A1 CN 1180352 A , B CZ 9703257 A3 EE 9700227 A WO 9632386 A1 EP 0824530 A1 HR 960168 A1 HU 9802270 A2 IL 117888 A JP 11503441 T NO 974734 A PL 322768 A1 RU 2167866 C2 SK 138797 A3 TR 9701173 T1 TW 449590 B US 6121262 A US 6251909 B1 US 6294556 B1 US 5710155 A US 2001011093 A1 US 6124296 A US 5861509 A ZA 9602916 A	17-10-1996 10-06-1999 30-10-1996 31-03-1999 29-05-1998 09-06-1998 17-10-1996 29-04-1998 17-06-1998 15-04-1998 17-10-1996 25-02-1998 31-08-1997 28-09-1999 21-11-2000 26-03-1999 13-10-1997 16-02-1998 27-05-2001 04-03-1998 21-03-1998 11-08-2001 19-09-2000 26-06-2001 25-09-2001 20-01-1998 02-08-2001 26-09-2000 19-01-1999 14-10-1996
WO 9634864	A	07-11-1996	US 5719156 A AU 705683 B2 AU 5714196 A BR 9608245 A CA 2218887 A1 CZ 9703423 A3 EP 0823906 A1 HU 9801382 A2 JP 11504921 T NO 975028 A NZ 307716 A PL 323235 A1 SK 147297 A3 WO 9634864 A1 US 5981520 A US 5798359 A US 5795894 A AT 202776 T AU 708834 B2 AU 6997996 A BR 9610277 A CA 2228370 A1	17-02-1998 27-05-1999 21-11-1996 04-05-1999 07-11-1996 18-03-1998 18-02-1998 28-06-1999 11-05-1999 30-12-1997 28-10-1999 16-03-1998 08-07-1998 07-11-1996 09-11-1999 25-08-1998 18-08-1998 15-07-2001 12-08-1999 19-03-1997 06-07-1999 06-03-1997

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/JP 01/11240

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9634864 A		CN 1200120 A	25-11-1998
		CZ 9800228 A3	15-07-1998
		DE 69613705 D1	09-08-2001
		EP 0850236 A1	01-07-1998
		ES 2158345 T3	01-09-2001
		HU 9802552 A2	28-10-1999
		WO 9708166 A1	06-03-1997
		JP 10511105 T	27-10-1998
		JP 2000344766 A	12-12-2000
		NO 980848 A	30-04-1998
		NZ 318493 A	28-10-1999
		PL 325339 A1	20-07-1998
		SK 27498 A3	02-12-1998
		US 5892039 A	06-04-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.